Methods of Treating Diseases and Disorders
Patent Information
- Application Number
- JP2023529966
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-18
- Filing Date
- 2021-11-17
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for additional therapies for the treatment of cancers and diseases associated with IRAK4, particularly non-Hodgkin lymphoma and other hematological malignancies, as existing treatments have limited efficacy and are not universally effective.
A method involving the measurement of phosphorylated NF-κB expression in a biological sample, followed by administration of an IRAK4-modifying compound such as an IRAK4 inhibitor or degrader, specifically targeting increased expression levels of NF-κB to modulate the IRAK4 pathway, thereby treating diseases like non-Hodgkin lymphoma and other IRAK4-related disorders.
The method effectively reduces tumor growth and improves treatment outcomes in non-Hodgkin lymphoma and other IRAK4-related disorders by inhibiting the NF-κB signaling pathway, demonstrating a synergistic effect with existing therapies and showing favorable pharmacokinetic profiles.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical Field
[0001] Related Applications This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 115,317, filed on November 18, 2020.
Background Art
[0002] Interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) is a serine / threonine kinase enzyme that plays an indispensable role in signal transduction mediated by the Toll / IL-1 receptor (TIR). Diverse IRAK enzymes are important components in signal transduction pathways mediated by interleukin-1 receptors (IL-1R) and Toll-like receptors (TLR) (Janssens, S, et al. Mol. Cell. 11, 2003, 293-302). The mammalian IRAK family consists of four members: IRAK1, IRAK2, IRAKM3, and IRAK4. These proteins are characterized by a typical N-terminal death domain and a centrally located kinase domain that mediates interactions with MyD88 family adapter proteins. IRAK proteins and MyD88 have been shown to play a role in the transmission of signals other than those derived from the IL-1R receptor, including signals induced by the activation of the IL-18 receptor (Kanakaraj, et al. J. Exp. Med. 189(7):1999, 1129-38) and the LPS receptor (Yang, et al., J. Immunol. 163, 1999, 639-643). Of the four members of the mammalian IRAK family, IRAK4 is considered the "master IRAK." Under overexpression conditions, all IRAKs can mediate the activation of the nuclear factor-κB (NF-κB) and stress-induced mitogen-activated protein kinase (MAPK) signaling cascades. However, only IRAK-1 and IRAK4 have been shown to possess active kinase activity.IRAK-1 kinase activity is not required for its function in IL-1-induced NF-κB activation (Kanakaraj et al., J.Exp.Med.187(12), 1998, 2073-2079) and (Xiaoxia Li, et al, Mol.Cell.Biol.19(7), 1999, 4643-4652), but IRAK4 requires kinase activity for signal transduction (Li S, et al. Proc.Natl.Acad.Sci.USA99(8), 2002, 5567-5572) and (Lye, E et al, J.Biol.Chem.279(39); 2004, 40653-8). Given the central role of IRAK4 in Toll-like / IL-1R signaling and immunological defense, IRAK4 inhibitors are associated with valuable therapeutics in inflammatory diseases, sepsis, and autoimmune disorders (Wietek C, et al, Mol. Interv. 2: 2002, 212-215).
[0003] Mice lacking IRAK4 are viable and exhibit complete suppression of inflammatory cytokine production in response to IL-1, IL-18, or LPS (Suzuki et al. Nature, 416(6882), 2002, 750-756). Similarly, human patients lacking IRAK4 are severely immunocompromised and unresponsive to these cytokines (Medvedev et al. J. Exp. Med., 198(4), 2003, 521-531 and Picard et al. Science 299(5615), 2003, 2076-2079). Knock-in mice containing inactive IRAK4 were completely resistant to lipopolysaccharide and CpG-induced shock (Kim TW, et al. J Exp Med204:2007, 1025-36) and (Kawagoe T, et al. J Exp Med204(5):2007, 1013-1024), demonstrating that IRAK4 kinase activity is essential for TLR ligand-responsive cytokine production, MAPK activation, and induction of NF-κB regulatory genes (Koziczak-Holbro M, et al. J Biol Chem;282(18):2007;13552-13560). Inactivation of IRAK4 kinase (IRAK4 KI) in mice leads to resistance to EAEs, resulting in reduced infiltration of inflammatory cells into the CNS and decreased antigen-specific CD4+ T cell-mediated IL-17 production (Kirk A et al. The Journal of Immunology, 183(1), 2009, 568-577).
[0004] Non-Hodgkin lymphoma (NHL) is the most common hematological malignancy in adults, with an estimated 78,000 new cases and approximately 20,000 deaths in the United States in 2020. While the molecular pathologies driving NHL are diverse, a common thread is the activation of the NF-κB signaling pathway. Specific molecular changes identified that drive this pathway constitute a subset of NHL. For example, diffuse large B-cell lymphoma (DLBCL) is an invasive lymphoma that can occur outside the lymph nodes or lymphatic system, in the gastrointestinal tract, testes, thyroid gland, skin, breast, bone, or brain. DLBCL is a cancer of B cells, a type of white blood cell responsible for antibody production. It is the most common type of non-Hodgkin lymphoma among adults, with an annual incidence of 7-8 cases per 100,000 people. This cancer primarily occurs in the elderly, with a median age of diagnosis of approximately 70 years, although in rare cases it can occur in children and young adults. DLBCL is an invasive tumor, and the first sign of the disease is typically the rapid growth of a mass. The five-year survival rate is only 58%. DLBCL is named according to the cells of its origin and has subtypes, including germinal center B-cell-like (GCB) and activated B-cell-like (ABC). They differ in that they have a worse prognosis and, in some cases, require a specialized approach to treatment.
[0005] Another example of NHL is Waldenstrom's macroglobulinemia (WM). WM is a non-Hodgkin lymphoma affecting two types of B cells: lymphoplasmacytoid cells and plasma cells. WM is characterized by high levels of circulating antibodies, immunoglobulin M (IgM), produced and secreted by the cells involved in the disease. WM is a rare disease, with only about 1,500 cases reported annually in the United States. There is no single approved treatment for WM, and clinical outcomes vary significantly due to differences in knowledge of the molecular basis of the disease. Objective response rates are high (>80%), but complete response rates are low (0-15%).
[0006] Other types of non-Hodgkin lymphoma include mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CNS lymphoma, and testicular lymphoma. Non-Hodgkin lymphoma can be caused by a variety of factors, including infections (Epstein-Barr virus, hepatitis C virus, and human T-cell leukemia virus), radiation and chemotherapy, and autoimmune diseases. As a group, 2.1% of the U.S. population will be affected by non-Hodgkin lymphoma at some point in their lives. The survival rate beyond 5 years after diagnosis is 71%.
[0007] Considering the above, there is a clear and unmet need for additional therapies for the treatment of cancer and other IRAK4-related diseases. [Overview of the project]
[0008] In certain aspects, this disclosure provides a method for treating a disease or disorder in a subject, and this method is Obtaining biological samples from the subject, Measuring the expression of phosphorylated NF-κB in biological samples, The level of phosphorylated NF-κB expression is compared to the level of phosphorylated NF-κB expression in the reference, If the expression of phosphorylated NF-κB is elevated compared to the reference level of phosphorylated NF-κB expression, administer an IRAK4-modified compound selected from IRAK4 inhibitors or IRAK4 degraders to the target patient. Includes.
[0009] In certain embodiments, the present disclosure provides a method for detecting increased expression of phosphorylated NF-κB p50 (p-p50) in a biological sample, the method being: The process involves contacting a biological sample with a primary antibody specific to NF-κB p-p50, thereby generating an antibody-NF-κB p-p50 complex. The method involves contacting an antibody-NF-κB p-p50 complex with a secondary antibody to produce an antibody / antibody complex mixture, wherein the secondary antibody is specific to the primary antibody and possesses enzymatic activity. The process involves treating an antibody / antibody complex mixture with a chromogenic substrate for enzyme activity, thereby generating a substrate / antibody / antibody complex mixture. Counterstaining of the substrate / antibody / antibody complex mixture, Includes. [Brief explanation of the drawing]
[0010] [Figure 1] This shows a dose-dependent objective response in human patients who received a specific dose of compound 1. [Figure 2]This is a schematic diagram of the IRAK1 / 4 complex with the adapter protein MYD88. After the substrate binds to IL-R1 or TLR, MYD88 activation recruits the IRAK4 / 1 complex, enabling IRAK-1 phosphorylation. Phosphorylated IRAK-1 then binds to TRAF-6, activating NF-κB signaling and causing inflammation and tumorigenesis. The MYD88-L265P mutation results in persistent upregulation of this pathway. Compound 1 inhibits IRAK4. [Figure 3] This shows a dose-dependent objective response in human patients who received a specific dose of compound 1. [Figure 4] This shows the response of a specific human patient who received compound 1. [Figure 5A] This study demonstrates the efficacy of compound 1 against a specific in vivo model of non-Hodgkin lymphoma. Administration of compound 1 reduced tumor growth. [Figure 5B] This study demonstrates the efficacy of compound 1 against a specific in vivo model of non-Hodgkin lymphoma. Administration of compound 1 reduced tumor growth. [Figure 5C] This study demonstrates the efficacy of compound 1 against a specific in vivo model of non-Hodgkin lymphoma. Administration of compound 1 reduced tumor growth. [Figure 6] The efficacy of compound 1 in combination with ibrutinib is demonstrated. The combination of compound 1 and ibrutinib showed a synergistic reduction in tumor growth compared to compound 1 or ibrutinib alone. [Figure 7] The oral pharmacological profile of compound 1 at exemplary doses in humans is shown. After oral administration, compound 1 is rapidly absorbed, with peak plasma concentrations observed 0.5–8 hours post-administration. Compound 1 shows dose-proportional exposure increase and has a half-life of approximately 6 hours. After multiple single daily doses, minimal to no accumulation is observed. Moderate accumulation is observed at steady state after multiple twice-daily doses. In summary, the oral pharmacokinetics of compound 1 are favorable. [Figure 8]This shows the percentage reduction in tumor volume in subjects who received 300 mg BID. Compound 1 has an acceptable safety and tolerability profile in RP2D, including 3 patients during a 1-2 year study. [Figure 9A] This paper demonstrates the effect of exemplary concentrations of compound 1 on erythrocyte differentiation from primary MDS / AML hematopoietic stem cells and progenitor cells (HSCPs). [Figure 9B] This paper demonstrates the effect of exemplary concentrations of compound 1 on neutrophil differentiation from primary MDS / AML hematopoietic stem cells and progenitor cells (HSCPs). [Figure 10A] This shows the effect of compound 1 on spleen weight in a leukemia Xerograph after treatment with 12.5 mg / kg for 6 weeks. [Figure 10B] This shows the effect of compound 1 on liver weight in a leukemia Xerograph after treatment with 12.5 mg / kg for 6 weeks. [Figure 10C] This shows the effect of compound 1 on the percentage of leukemia cells in the bone marrow in the leukemia xerograph after treatment with 12.5 mg / kg for 6 weeks. Compound 1 reduced the disease burden in the THP-1 xerograph. [Figure 11] The design of the test described in Example 4 is shown below. [Figure 12A] This study demonstrates the effect of compound 1 on NF-κB phospho-p50 expression. NF-κB phospho-p50 protein expression in pre-treatment biopsy samples correlated with lymphoma contraction or disease stabilization. SD refers to disease stabilization, and PD refers to disease progression. [Figure 12B] This shows the effect of compound 1 on NF-κB phospho-p50 expression. Inhibition of NF-κB phospho-p50 expression indicates that compound 1 inhibits IRAK4 and downregulates NF-κB. NF-κB phospho-p50 expression is inhibited (changes from positive to negative) while treated with compound 1. [Figure 12C] This shows the expression of NF-κB phospho-p50 in human tonsillar cells and lymphoma cells. NF-κB phospho-p50 expression is increased in lymphoma cells. [Figure 13A]This is a Western blot of OCL-LY10 cells treated with DMSO or compound 1. Treatment with compound 1 downregulated the expression of NF-κB phospho-p50. [Figure 13B] This is a Western blot of AML cells treated with DMSO or compound 1. Treatment with compound 1 downregulated the expression of NF-κB phospho-p50. [Figure 14A] This is a representative photograph of an FFPE BM sample obtained from an AML patient, showing that NF-κB p-p50 is expressed in the sample. [Figure 14B] This is a representative photograph of an FFPE BM sample obtained from an AML patient, showing that NF-κB p-p50 is expressed in the sample. [Modes for carrying out the invention]
[0011] When IRAK4 is activated, the NF-κB signaling pathway is activated, including the phosphorylation of NF-κB p50, which is necessary for NF-κB DNA binding and transcriptional activity (Hou S et al. Phosphorylation of serine 337 of NF-κB p50 is critical for DNA binding. J Biol Chem. 2003). Increased cellular expression levels of NF-κB p-p50 and activation of NF-κB indicate the expression of biologically active IRAK4 in cells.
[0012] In one aspect, the disclosure provides a method for treating a disease or disorder in a subject, and this method is Obtaining biological samples from the subject, Measuring the expression of phosphorylated NF-κB in biological samples, The level of phosphorylated NF-κB expression is compared to the level of phosphorylated NF-κB expression in the reference, If the expression of phosphorylated NF-κB is elevated compared to the reference level of phosphorylated NF-κB expression, administer an IRAK4-modified compound selected from IRAK4 inhibitors or IRAK4 degraders to the target patient. Includes.
[0013] In another aspect, the Disclosure provides a method for treating IRAK4-mediated diseases or disorders in a subject, the method being: Obtaining biological samples from the subject, Measuring the expression of phosphorylated NF-κB in biological samples, The level of phosphorylated NF-κB expression is compared to the level of phosphorylated NF-κB expression in the reference, If the expression of phosphorylated NF-κB is elevated compared to the reference level of phosphorylated NF-κB expression, administer an IRAK4-modified compound selected from IRAK4 inhibitors or IRAK4 degraders to the target patient. Includes.
[0014] In yet another aspect, the Disclosure provides a method for treating a disease or disorder in a subject, the method being: Obtaining biological samples from the subject, Measuring the expression of phosphorylated NF-κB in biological samples, The level of phosphorylated NF-κB expression is compared to the level of phosphorylated NF-κB expression in the reference, If the expression of phosphorylated NF-κB is not elevated compared to the reference level of phosphorylated NF-κB expression, then administer a drug that is not an IRAK4-modified compound. Includes.
[0015] In certain embodiments, the method described above further includes obtaining a reference. In certain embodiments, the reference is a value obtained from one or more subjects that are not suffering from disease or disorder. In certain preferred embodiments, the value is obtained from the same biological source as the biological sample (e.g., tissue, blood, or other bodily fluids). In certain embodiments, the value is obtained from tissue or blood.
[0016] In certain preferred embodiments, phosphorylated NF-κB is NF-κB p-p50. In certain preferred embodiments, the method comprises administering an IRAK4 inhibitor or IRAK4 degrader to a target if NF-κB p-p50 expression is elevated. In certain embodiments, NF-κB p-p50 expression is nuclear expression. In certain embodiments, NF-κB p-p50 expression is cytoplasmic expression. In certain embodiments, NF-κB p-p50 expression is a combination of nuclear and cytoplasmic expression.
[0017] In certain preferred embodiments, phosphorylated NF-κB is NF-κB p-p65. In certain preferred embodiments, the method comprises administering an IRAK4 inhibitor or IRAK4 degrader to a target if NF-κB p-p65 expression is elevated. In certain embodiments, NF-κB p-p65 expression is nuclear expression. In certain embodiments, NF-κB p-p65 expression is cytoplasmic expression. In certain embodiments, NF-κB p-p65 expression is a combination of nuclear and cytoplasmic expression.
[0018] In another aspect, the present disclosure provides a method for detecting elevated NF-κB p-p50 expression in a biological sample, the method being: The process involves contacting a biological sample with a primary antibody specific to NF-κB p-p50, thereby generating an antibody-NF-κB p-p50 complex. The method involves contacting an antibody-NF-κB p-p50 complex with a secondary antibody to produce an antibody / antibody complex mixture, wherein the secondary antibody is specific to the primary antibody and possesses enzymatic activity. The process involves treating an antibody / antibody complex mixture with a chromogenic substrate for enzyme activity, thereby generating a substrate / antibody / antibody complex mixture. Counterstaining of the substrate / antibody / antibody complex mixture, Includes.
[0019] In certain embodiments, counterstaining of the substrate / antibody / antibody complex mixture is performed for 60 seconds or less. In certain embodiments, counterstaining of the substrate / antibody / antibody complex mixture is performed for 10 seconds or less.
[0020] In certain embodiments, the counterstain is hematoxylin.
[0021] In certain embodiments, the enzyme activity is peroxidase activity. In certain embodiments, the chromogenic substrate is a peroxidase substrate.
[0022] In other embodiments, the enzyme activity is alkaline phosphatase activity. In certain embodiments, the chromogenic substrate is a phosphatase substrate.
[0023] In certain embodiments, the primary antibody is a monoclonal antibody. In certain embodiments, the secondary antibody is a monoclonal antibody.
[0024] IRAK4 inhibitors More broadly, the methods disclosed herein may be carried out using any IRAK4 inhibitor. For example, the methods may be carried out using the IRAK4 inhibitors disclosed in PCT / IB2015 / 050119, PCT / IB2015 / 050217, PCT / IB2015 / 0054620, PCT / IB2016 / 054203, and / or PCT / IB2016 / 054229, the contents of each of the aforementioned international applications being fully incorporated herein by reference.
[0025] In a particular embodiment, the IRAK4 inhibitor is expressed by formula I: [ka] or a pharmaceutically acceptable salt thereof Represented by, During the ceremony, X1 and X3 are independently CH or N, and X2 is CR2 or N, provided that only one of X1, X2, or X3 is N. A is either O or S, Y is either -CH2- or O. Z is an aryl or heterocyclyl, R1 is a heterocyclyl that is independently substituted with a halo or of any choice, and the substituents may be alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl, or -NR a R b And, R2 is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or -NR a R b The substituents are alkyl, amino, halo, or hydroxyl. R3 is either alkyl or hydroxyl, depending on its presence. R a and R b These are independently hydrogen, alkyl, acyl, or heterocyclyl. "m" and "n" are independently 0, 1, or 2. "p" is 0 or 1.
[0026] In certain embodiments, A is O or S, Y is -CH2- or O, Z is aryl or heterocyclyl, R1 is, independently for each occurrence, halo or optionally substituted heterocyclyl, and the substituent is alkyl, aminoalkyl, halo, or -NR a R b where R a and R b are independently hydrogen, alkyl, or heterocyclyl, R2 is hydrogen, cycloalkyl, heterocyclyl, or -NR a R b and "m" is 0 and "n" is 1.
[0027] In other embodiments, A is O or S, Y is -CH2- or O, Z is aryl or heterocyclyl, R1 is, independently for each occurrence, halo or optionally substituted heterocyclyl, and the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, or -NR a R b where R a and R b are independently hydrogen, alkyl, or heterocyclyl, R2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl, or -NR a R b and the substituent is selected from amino, halo, or hydroxyl, and "m" and "n" are independently 0, 1, or 2, and "p" is 0 or 1.
[0028] In certain embodiments
Chemical formula
Chemical formula
[0029] In certain embodiments, Z is an aryl or a 5-membered or 6-membered heterocyclyl. In certain embodiments, Z is phenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1H-tetrazolyl, oxadiazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridadinyl, azetidinyl, oxetanyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydrofuranyl The optionally substituted heterocyclils selected from trahydropyranil, morpholinil, thiomorpholinil, 1,4-dioxanil, dioxidethiomorpholinil, oxapiperazinil, oxapiperidinil, tetrahydrofuryl, tetrahydropyranil, tetrahydrothiophenyl, dihydropyranil, and azabicyclo[3.2.1]octanil, each of which is alkyl, alkoxy, halo, hydroxyl, hydroxyalkyl, or -NR a R b Replaced by R a and R b These are independently hydrogen, alkyl, or acyl.
[0030] In a particular embodiment, the IRAK4 inhibitor is expressed by formula (IA): [ka] or represented by a pharmaceutically acceptable salt thereof. In certain embodiments, A is O or S, Y is -CH2- or O, and R1 is independently, in each presence, a halo or optionally substituted heterocycline, where the substituent is alkyl, aminoalkyl, halo, or -NR a R b And R a and R b R2 is independently hydrogen, alkyl, or heterocycline, and R2 is hydrogen, cycloalkyl, heterocycline, or -NR a R bIn this embodiment, "m" is 0 and "n" is 1. In other embodiments, A is O or S, Y is -CH2- or O, and R1 is independently a halo or optionally substituted heterocyclyl in each presence, where the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, or -NR a R b And R a and R b R2 is independently hydrogen, alkyl, or heterocycline, and R2 is hydrogen, cycloalkyl, optionally substituted heterocycline, or -NR a R b The substituent is selected from amino, halo, or hydroxyl, and "m" and "n" are independently 0, 1, or 2.
[0031] In a particular embodiment, the IRAK4 inhibitor is expressed by formula (IB): [ka] or represented by a pharmaceutically acceptable salt thereof. In certain embodiments, A is O or S, Y is -CH2- or O, and R1 is independently, in each presence, a halo or optionally substituted heterocycline, where the substituent is alkyl, aminoalkyl, halo, or -NR a R b And R a and R b R2 is independently hydrogen, alkyl, or heterocycline, and R2 is hydrogen, cycloalkyl, heterocycline, or -NR a R b In other embodiments, A is O or S, Y is -CH2- or O, and R1 is independently a halo or optionally substituted heterocyclyl in each presence, where the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, or -NR a R b And R a and R bR2 is independently hydrogen, alkyl, or heterocycline, and R2 is hydrogen, cycloalkyl, optionally substituted heterocycline, or -NR a R b The substituent is selected from amino, halo, or hydroxyl, and "m" and "n" are independently 0, 1, or 2.
[0032] In a particular embodiment, the IRAK4 inhibitor is expressed by formula (IC): [ka] or represented by a pharmaceutically acceptable salt thereof.
[0033] In certain embodiments, R1 is an optionally substituted heterocycline, where the substituents are alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl, or -NR a R b And R a and R b R1 is independently hydrogen or acyl. In other embodiments, R1 is optionally substituted heterocycline, where the substituent is alkyl, aminoalkyl, halo, or -NR a R b And R a and R b R1 is independently hydrogen or acyl. In yet another embodiment, R1 is optionally substituted heterocycline, where the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, or -NR a R b And R a and R b R1 is independently hydrogen, alkyl, or heterocyclyl. In certain embodiments, R1 is pyridyl, pyrazolyl, pyrrolidinyl, or piperidinyl. In certain embodiments, R1 is optionally substituted pyrazolyl, where the substituent is alkyl, hydroxyl, or -NR a R b In other embodiments, R1 is a halo.
[0034] In certain embodiments, R2 is hydrogen, a cycloalkyl, an optionally substituted heterocycline, or -NR a R b The substituent is selected from amino, halo, or hydroxyl. In certain embodiments, R2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl, or -NR a R b The substituent is selected from amino, halo, or hydroxyl. In certain embodiments, R2 is an optionally substituted heterocyclyl selected from piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, azetidinyl, pyrazolyl, furanil, or azabicyclo[3.2.1]octanil, and the substituent is hydroxyl, halo, alkyl, or amino. In certain embodiments, R2 is piperidinyl, pyrrolidinyl, morpholinyl, or piperazinyl. In other embodiments, R2 is hydrogen. In yet another embodiment, is a cycloalkyl. In certain embodiments, R2 is cyclopropyl.
[0035] In a particular embodiment, R3 is an alkyl group.
[0036] In one particular embodiment, m is 0 and p is 1. In other embodiments, m is 0 or 2 and p is 0 or 1.
[0037] In a particular embodiment, the IRAK4 inhibitor is 6'-amino-N-(2-morpholinoxazolo[4,5-b]pyridine-6-yl)-[2,3'-bipyridine]-6-carboxamide, 6'-amino-N-(5-cyclopropyl-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-[2,3'-bipyridine]-6-carboxamide hydrochloride, N-(5-cyclopropyl-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide hydrochloride, N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-6-(1H-pyrazole-4-yl)picolinamide hydrochloride, N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-6-(1H-pyrazole-4-yl)picolinamide, 2-(2-methylpyridine-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 6-Chloro-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)picolinamide, N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-6-(1-methyl-1H-pyrazole-4-yl)picolinamide, 2-(2-chloropyridine-4-yl)-N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, (S)-2-(2-methylpyridine-4-yl)-N-(2-morpholino-5-(pyrrolidine-3-ylamino)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 6'-amino-N-(2-morpholinoxazolo[5,4-b]pyridine-5-yl)-[2,3'-bipyridine]-6-carboxamide, 6'-amino-N-(2-morpholinothiazolo[4,5-c]pyridine-6-yl)-[2,3'-bipyridine]-6-carboxamide, 6'-amino-N-(2-morpholinothiazolo[5,4-b]pyridine-5-yl)-[2,3'-bipyridine]-6-carboxamide, 2-(2-methylpyridine-4-yl)-N-(2-morpholinothiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 6'-amino-N-(2-morpholinothiazolo[4,5-b]pyridine-6-yl)-[2,3'-bipyridine]-6-carboxamide, N-(2-morpholinothiazolo[4,5-b]pyridine-6-yl)-6-(1H-pyrazole-4-yl)picolinamide, 3-(4-(aminomethyl)piperidine-1-yl)-5-fluoro-N-(2-morpholinothiazolo[4,5-b]pyridine-6-yl)benzamide, 2-(4-(aminomethyl)piperidine-1-yl)-5-fluoro-N-(2-morpholinothiazolo[4,5-b]pyridine-6-yl)benzamide, 2-(2-methylpyridine-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-6-(1H-pyrazole-4-yl)picolinamide, N-(2,5-di(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-6-(1H-pyrazole-4-yl)picolinamide, N-(2,5-di(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(2,5-dimorpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(4-methylpiperazine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-2-(6-methoxypyridine-3-yl)oxazole-4-carboxamide, N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-3-yl)oxazole-4-carboxamide, N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-2-(2-hydroxypyridine-3-yl)oxazole-4-carboxamide, 2-(2-hydroxypyridine-3-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-2-(6-hydroxypyridine-3-yl)oxazole-4-carboxamide, 2-(2-methoxypyridine-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 2-(2-methylpyridine-3-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 2-(3-methylpyridine-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-2-(3-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(6-methylpyridine-3-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 6-(1-methyl-1H-pyrazole-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)picolinamide, N-(2,5-di(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-2-(6-methylpyridine-3-yl)oxazole-4-carboxamide, (S)-N-(5-(3-aminopyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (S)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (R)-N-(5-(3-aminopyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (R)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (S)-2-(3-aminopyrrolidine-1-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, (S)-6-(3-hydroxypyrrolidine-1-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)picolinamide, (S)-6-(3-aminopyrrolidine-1-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)picolinamide, (S)-2-(3-hydroxypyrrolidine-1-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, (S)-N-(5-cyclopropyl-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(3-hydroxypyrrolidine-1-yl)oxazole-4-carboxamide, (S)-2-(3-aminopyrrolidine-1-yl)-N-(5-cyclopropyl-2-morpholinoxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 2-(2-methylpyridine-4-yl)-N-(5-(piperidine-1-yl)-2-(pyrrolidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide hydrochloride, N-(2-(2,6-dimethylmorpholino)-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide hydrochloride, N-(2,5-di(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-6-(1-methyl-1H-pyrazole-4-yl)picolinamide hydrochloride, 6-(1-methyl-1H-pyrazole-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)picolinamide, N-(2,5-di(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-3-yl)oxazole-4-carboxamide hydrochloride, N-(2-((2S,6R)-2,6-dimethylmorpholino)-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridine-3-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 2-(2-hydroxypyridine-3-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, N-(2,5-di(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-2-(2-methoxypyridine-4-yl)oxazole-4-carboxamide, 2-(6-methoxypyridine-3-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 2-(2-methoxypyridine-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, (S)-N-(5-(3-fluoropiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(6-methylpyridine-3-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 2-(3-methylpyridine-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, (S)-6-(3-aminopyrrolidine-1-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)picolinamide, (S)-6-(3-hydroxypyrrolidine-1-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)picolinamide, (S)-6-(3-aminopyrrolidine-1-yl)-N-(2,5-di(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)picolinamide, (S)-N-(2,5-di(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-6-(3-hydroxypyrrolidine-1-yl)picolinamide, (S)-2-(3-aminopyrrolidine-1-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, (S)-N-(5-(3-aminopyrrolidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (S)-2-(3-aminopyrrolidine-1-yl)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (S)-2-(3-hydroxypyrrolidine-1-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, (S)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-6-(3-hydroxypyrrolidine-1-yl)picolinamide, (S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(3-hydroxypyrrolidine-1-yl)oxazole-4-carboxamide, (S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-6-(1-(2-hydroxypropyl)-1H-pyrazole-4-yl)picolinamide, (S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(1-(2-hydroxypropyl)-1H-pyrazole-4-yl)oxazole-4-carboxamide, N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(6-methoxypyridine-3-yl)oxazole-4-carboxamide, (S)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(6-methoxypyridine-3-yl)oxazole-4-carboxamide, (R)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(6-methoxypyridine-3-yl)oxazole-4-carboxamide, (S)-N-(5-(azetidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-6-(3-hydroxypyrrolidine-1-yl)picolinamide, N-(5-(3-hydroxyazetidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (S)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)thiophene-2-carboxamide, (S)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)furan-2-carboxamide, (S)-N-(5-(3-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide (R)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)furan-2-carboxamide, N-(5-(azetidine-1-yl)-2-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridine-4-yl)-N-(2-(piperidine-1-yl)-5-(pyrrolidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 2-(2-methylpyridine-4-yl)-N-(2-morpholino-5-(pyrrolidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 5-(2-methylpyridine-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)furan-2-carboxamide, N-(5-(azepan-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(2-aminopyridine-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide hydrochloride, N-(5-(azetidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (R)-N-(5-(3-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (R)-N-(5-(3-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)furan-2-carboxamide, (S)-6-(1-(2-hydroxypropyl)-1H-pyrazole-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)picolinamide N-(5-(4-fluoropiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)furan-2-carboxamide N-(5-(4-fluoropiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide hydrochloride N-(5-(1-methyl-1H-pyrazole-4-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(3-fluorophenyl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)furan-2-carboxamide, N-(5-(3-fluoropiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)furan-2-carboxamide, (S)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(6-methoxypyridine-3-yl)oxazole-4-carboxamide, N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (R)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(6-methoxypyridine-3-yl)oxazole-4-carboxamide, N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(6-methoxypyridine-3-yl)oxazole-4-carboxamide, (S)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)furan-2-carboxamide, (S)-N-(5-(3-hydroxypyrrolidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)thiophene-2-carboxamide, N-(5-(azetidine-1-yl)-2-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridine-4-yl)-N-(2-(piperidine-1-yl)-5-(pyrrolidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 5-(2-methylpyridine-4-yl)-N-(2-morpholino-5-(piperidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)furan-2-carboxamide, N-(5-(azetidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridine-4-yl)-N-(2-morpholino-5-(pyrrolidine-1-yl)oxazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)furan-2-carboxamide, (R)-N-(5-(3-hydroxypiperidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-5-(2-methylpyridine-4-yl)furan-2-carboxamide, N-(5-(furan-3-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(3-fluoropiperidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(4-fluoropiperidine-1-yl)-2-morpholinoxazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, (S)-N-(5-(3-aminopiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridine-4-yl)-N-(2-morpholino-5-(1H-pyrazole-4-yl)thiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, N-(5-(6-fluoropyridine-3-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(2-(3-hydroxypiperidine-1-yl)-5-(piperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(2-acetamidopyridine-4-yl)-N-(5-(4-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, N-(2-(3-hydroxypiperidine-1-yl)-5-(4-hydroxypiperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, 2-(2-acetamidopyridine-4-yl)-N-(5-(3-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide, 2-(2-aminopyridine-4-yl)-N-(5-(3-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide hydrochloride, 5-(2-aminopyridine-4-yl)-N-(5-(4-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)furan-3-carboxamide hydrochloride, 2-(2-aminopyridine-4-yl)-N-(5-(4-hydroxypiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide hydrochloride, 2-(2-aminopyridine-4-yl)-N-(5-(4-fluoropiperidine-1-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)oxazole-4-carboxamide hydrochloride, N-(5-(2-fluoropyridine-4-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(4-fluoropiperidine-1-yl)-2-(3-hydroxypiperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide, N-(5-(4-aminopiperidine-1-yl)-2-(3-hydroxypiperidine-1-yl)thiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide hydrochloride, and N-(5-(2-hydroxypyridine-4-yl)-2-morpholinothiazolo[4,5-b]pyridine-6-yl)-2-(2-methylpyridine-4-yl)oxazole-4-carboxamide hydrochloride, Alternatively, it may be selected from a pharmaceutically acceptable salt or stereoisomer thereof.
[0038] In a particular embodiment, the IRAK4 inhibitor is [ka] That is the case.
[0039] In a particular preferred embodiment, the IRAK4 inhibitor is [ka] In other preferred embodiments, the IRAK4 inhibitor is [ka] It is a pharmaceutically acceptable salt.
[0040] Compound 1 can be administered in any amount or manner that elicits a desired response in the subject. For example, 100-400 mg of Compound 1 can be administered to a subject twice daily, or 200-1000 mg of Compound 1 can be administered to a subject once daily. In certain embodiments, 100-400 mg of Compound 1 is administered to the subject twice daily. In certain embodiments, 200-400 mg of Compound 1 is administered to the subject twice daily. In certain preferred embodiments, 250-350 mg of Compound 1 is administered to the subject twice daily. In certain embodiments, compound 1 is administered twice daily in amounts of approximately 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, or 500 mg. In certain embodiments, compound 1 is administered twice daily in amounts of approximately 50 mg, 75 mg, 100 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, or 400 mg. In certain embodiments, approximately 50 mg, approximately 100 mg, approximately 200 mg, or approximately 300 mg of compound 1 is administered to the subject twice daily. In certain embodiments, approximately 50 mg of compound 1 is administered to the subject twice daily. In other embodiments, approximately 200 mg of compound 1 is administered to the subject twice daily. In other embodiments, approximately 225 mg of compound 1 is administered to the subject twice daily. In other embodiments, approximately 250 mg of compound 1 is administered to the subject twice daily. In other embodiments, approximately 275 mg of compound 1 is administered to the subject twice daily. In a particularly preferred embodiment, approximately 300 mg of compound 1 is administered to the subject twice daily. In other embodiments, approximately 325 mg of compound 1 is administered to the subject twice daily. In other embodiments, approximately 350 mg of compound 1 is administered to the subject twice daily. In other embodiments, approximately 375 mg of compound 1 is administered to the subject twice daily. In another embodiment, approximately 400 mg of compound 1 is administered to the subject twice a day.
[0041] In certain embodiments, compound 1 is administered to the subject once daily in amounts of approximately 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, or 500 mg. In certain embodiments, compound 1 is administered to the subject once daily in amounts of approximately 50 mg. In certain embodiments, compound 1 is administered to the subject once daily in amounts of approximately 75 mg. In certain embodiments, compound 1 is administered to the subject once daily in amounts of approximately 100 mg. In certain embodiments, compound 1 is administered to the subject once daily in amounts of approximately 125 mg. In certain embodiments, compound 1 is administered to the subject once daily in amounts of approximately 150 mg.
[0042] In certain preferred embodiments, compound 1 is administered orally to the subject. In certain embodiments, about 50 mg of compound 1 is administered orally to the subject twice daily. In other embodiments, about 200 mg of compound 1 is administered orally to the subject twice daily. In other embodiments, about 250 mg of compound 1 is administered orally to the subject twice daily. In particularly preferred embodiments, about 300 mg of compound 1 is administered orally to the subject twice daily. In other embodiments, about 325 mg of compound 1 is administered orally to the subject twice daily. In other embodiments, about 350 mg of compound 1 is administered orally to the subject twice daily. In other embodiments, about 375 mg of compound 1 is administered orally to the subject twice daily. In other embodiments, about 400 mg of compound 1 is administered orally to the subject twice daily. In other embodiments, about 50 mg of compound 1 is administered orally to the subject once daily. In yet another embodiment, about 75 mg of compound 1 is administered orally to the subject once daily. In yet another embodiment, approximately 100 mg of compound 1 is administered to the subject once daily. In yet another embodiment, approximately 125 mg of compound 1 is administered to the subject once daily. In yet another embodiment, approximately 150 mg of compound 1 is administered to the subject once daily.
[0043] In other embodiments, the IRAK4 inhibitor is PF-06650833 or BAY1830839.
[0044] IRAK4 Decomposing Agent In certain embodiments, the method includes administering an IRAK4 degrading agent. In certain embodiments, the IRAK4 degrading agent is KT-474.
[0045] Combination therapy In certain embodiments of the methods disclosed herein, the method further comprises co-administration of a BCL-2 inhibitor. In certain preferred embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the method further comprises administering 400 mg of venetoclax daily. In certain embodiments, the venetoclax is administered orally. In certain preferred embodiments, the method further comprises administering 400 mg of venetoclax orally daily.
[0046] In other embodiments, the method further includes co-administration of a BTK inhibitor. In certain embodiments, the BTK inhibitor is ibrutinib, acalabrutinib, zanubrutinib, evobrutinib, ONO-4059, spebratinib, or HM7 1224. In certain embodiments, the BTK inhibitor is ibrutinib, acalabrutinib, zanubrutinib, evobrutinib, ONO-4059, spebratinib, or HM7 1224. In certain embodiments, the BTK inhibitor is acalabrutinib. In certain embodiments, the method includes administering 200 mg of acalabrutinib daily. In certain embodiments, acalabrutinib is administered orally. In certain embodiments, the method includes administering 200 mg of acalabrutinib orally daily. In certain preferred embodiments, the BTK inhibitor is ibrutinib. In certain embodiments, the method includes administering 420 mg of ibrutinib daily. In other embodiments, the method includes administering 420 mg of ibrutinib daily. In certain embodiments, ibrutinib is administered orally. In certain preferred embodiments, 420 mg of ibrutinib is administered orally daily. In other preferred embodiments, the method includes administering 560 mg of ibrutinib daily. In certain embodiments, the BTK inhibitor is zanubrutinib. In certain embodiments, the method includes administering 160 mg of zanubrutinib twice daily. In other embodiments, the method includes administering 320 mg of zanubrutinib once daily. In certain embodiments, zanubrutinib is administered orally. In certain embodiments, the method includes administering 160 mg of zanubrutinib twice daily. In other embodiments, the method includes administering 320 mg of zanubrutinib once daily. In a particular embodiment, the method involves ABT-737, BAY-1143572, 5-fluorouracil, abiraterone acetate, acetylcholine, ado-trastuzumab emtansine, afatinib, aldesleukin, alectinib, alemtuzumab, alitretinoin, aminolevulinic acid, anastrozole, anastrozole, aprepitant, arsenic trioxide, asparaginase, erwinia chrysanthemum, atezolizumab, axitinib, azacitidine, bellinostat,Bendamustine, benzyl isothiocyanate, bevacizumab, bexarotene, bicalutamide, bleomycin, blinatumomab, bortezomib, bosutinib, brentuximab vedotin, busulfan, cabazitaxel, cabozantinib, capecitabine, carboplatin, carfilzomib, carmustine, ceritinib, cetuximab, chlorambucil, cisplatin, clofarabine, cobimetinib, copanlisib, crizotinib, cyclophosphamide, cytarabine, dabrafenib, dacarbazine, dacarbazine, dactinomycin, daratumumab Dasatinib, daunorubicin, decitabine, defibrotide sodium, degarelix, denileukin difutox, denosumab, dexamethasone, dexrazoxane, dihydrotestosterone (DHT), dinutuximab, docetaxel, doxorubicin, elotuzumab, eltrombopag, enzalutamide, epirubicin, eribulin mesylate, erlotinib, etoposide, everolimus, exemestane, exemestane, filgrastim, fludarabine phosphate, flutamide, fulvestrant, fulvestrant, gefitinib, gemcitabine Gemtuzumab, gemtuzumab ozogamicin, glucarpidase, goserelin acetate, hydroxyurea, ibritumomab tiuxetan, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, imiquimod, interferon alpha-2b, ipilimumab, irinotecan, ixabepyrone, ixazomib, lanreotide, lapatinib, lenalidomide, lenvatinib, letrozole, leucovorin, leuprolide, lomustine, mechloretamine, megestrol acetate, melphalan, mercaptopurine, mesna, methotrexate Mitomycin C, Mitoxantrone, Navitoclax, Necitumumab, Nelarabine, Netupitant, Nilotinib, Niltamide, Nivolumab, Obinutuzumab, Ofatumumab, Olaparib, Omasetaxin / Mepesuccinate, Osimertinib, Oxaliplatin, Ozogamicin, Paclitaxel, Palbociclib, Palifermin, Pamidronate, Panitumumab, Panobinostat, Pazopanib, PegAsparagaze, Peginterferon Alpha-2b, Pembrolizumab, Pemetrexed, Pertuzumab, Prelixafor, Pomalidomide,Ponatinib, pralatrexate, prednisone, procarbazine, propranolol, radium-223 chloride, raloxifene, ramucirumab, rasburicase, regorafenib, rituximab, lorapitant, romidepsin, romiplostim, ruxolitinib, siltuximab, ciproisel-t, sonidecib, sorafenib, sunitinib, tarimozine / laharpalepbec, tamoxifen, temozolomide, temsirolimus, thalidomide, thioguanine, The treatment further includes co-administration of one or more of the following: thiotepa, tipiracil, topotecan, toremifene, tositumomab, trabectedin, trametinib, trastuzumab, tretinoin, trifluridine, uridine triacetate, vandetanib, vemurafenib, venetoclax, vinblastine, vincristine, vinorelbine, bismodegib, vorinostat, ziv-aflibercept, zoledronic acid, and pharmaceutically acceptable salts thereof. In some embodiments, the second therapeutic agent is one or more of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
[0047] Diseases and Disabilities The methods disclosed herein relate to the treatment of a number of diseases and disorders. For example, the methods may be used to treat diseases and disorders associated with IRAK4. In certain embodiments, the disease or disorder is cancer, preferably hematological malignancies, such as leukemia or lymphoma, such as non-Hodgkin lymphoma. In certain embodiments, hematological malignancies include myelogenous leukemia, myeloid leukemia (e.g., acute myeloid leukemia), myelodysplastic syndrome, lymphoblastic leukemia (e.g., acute lymphoblastic leukemia), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high-risk CLL, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL) (e.g., DLBCL or ABC-DLBLC), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), multiple myeloma, and marginal zone lymphoma. These include lymphoma (MZL), Burkitt lymphoma, non-Burkitt high-grade B-cell lymphoma, extranodal marginal zone B-cell lymphoma, transformed high-grade B-cell lymphoma (HGBL), lymphoplasmacytic lymphoma (LPL), central nervous system lymphoma (CNSL), or MALT lymphoma. In certain embodiments, the hematological malignancy is myeloid leukemia. In other embodiments, the hematological malignancy is myeloid leukemia (e.g., acute myeloid leukemia). In certain embodiments, the hematological malignancy is acute myeloid leukemia (e.g., AML). In certain embodiments, AML is primary AML. In other embodiments, AML is secondary AML. In yet another embodiment, the hematological malignancy is myelodysplastic syndrome. In certain embodiments, myelodysplastic syndromes are highly malignant.In other embodiments, myelodysplastic syndrome is low-grade. In specific embodiments, myelodysplastic syndrome is high-risk. In yet another embodiment, the hematological malignancy is lymphoblastic leukemia (e.g., acute lymphoblastic leukemia). In yet another embodiment, the hematological malignancy is chronic lymphocytic leukemia (CLL). In specific embodiments, the CLL is high-risk CLL. In yet another embodiment, the hematological malignancy is small lymphocytic lymphoma (SLL). In yet another embodiment, the hematological malignancy is follicular lymphoma. In yet another embodiment, the hematological malignancy is diffuse large B-cell lymphoma (DLBCL). In yet another embodiment, the hematological malignancy is activated B-cell-like (ABC) DLBCL. In yet another embodiment, the hematological malignancy is germinal center B-cell-like (GCB) DLBCL. In specific embodiments, the DLBCL is extranodal. In certain embodiments, DLBCL is extranodal leg lymphoma, extranodal testicular lymphoma, or extranodal not otherwise specified (NOS) type lymphoma. In yet another embodiment, the hematological malignancy is mantle cell lymphoma. In yet another embodiment, the hematological malignancy is Waldenström macroglobulinemia. In yet another embodiment, the hematological malignancy is multiple myeloma. In yet another embodiment, the hematological malignancy is marginal zone lymphoma. In yet another embodiment, the hematological malignancy is Burkitt lymphoma. In yet another embodiment, the hematological malignancy is non-Burkitt high-grade B-cell lymphoma. In yet another embodiment, the hematological malignancy is extranodal marginal zone B-cell lymphoma. In yet another embodiment, the hematological malignancy is transformed high-grade B-cell lymphoma (HGBL). In yet another embodiment, the hematological malignancy is lymphoplasmacytic lymphoma (LPL). In yet another embodiment, the hematological malignancy is CNS lymphoma. In yet another embodiment, the CNS lymphoma is primary CNS lymphoma (PCNSL). In yet another embodiment, the hematological malignancy is MALT lymphoma. In certain embodiments, the above hematological malignancy may be relapsed or refractory. In certain embodiments, the above hematological malignancy is resistant to treatment with BTK inhibitors.In certain embodiments, the hematological malignancies described above are resistant to treatment with BTK inhibitors as monotherapy. In certain embodiments, the hematological malignancies are resistant to treatment with ibrutinib, acalabrutinib, zanubrutinib, evobrutinib, ONO-4059, spebratinib, or HM7 1224. In certain preferred embodiments, the hematological malignancies are resistant to treatment with ibrutinib.
[0048] In certain embodiments, the cancer is selected from brain cancer, kidney cancer, liver cancer, stomach cancer, penile cancer, vaginal cancer, ovarian cancer, gastric cancer, breast cancer, bladder cancer, colon cancer, prostate cancer, pancreatic cancer, lung cancer, cervical cancer, epidermal cancer, prostate cancer, and head and neck cancer. In certain preferred embodiments, the cancer is pancreatic cancer. In other embodiments, the cancer is colon cancer. In certain embodiments, the cancer is a solid tumor. In various such embodiments, the cancer may be recurrent or refractory. In certain embodiments, the cancer is resistant to treatment with BTK inhibitors. In certain embodiments, the cancer is resistant to treatment with BTK inhibitors as monotherapy. In certain embodiments, the cancer is resistant to treatment with ibrutinib, acalabrutinib, zanubrutinib, evobrutinib, ONO-4059, spebratinib, or HM7 1224. In certain preferred embodiments, the cancer is resistant to treatment with ibrutinib.
[0049] In other embodiments, the disease or disorder is an inflammatory disease or disorder. In specific embodiments, the inflammatory disease or disorder is an autoimmune disease or disorder. In certain embodiments, inflammatory diseases or disorders include ocular allergies, conjunctivitis, keratoconjunctivitis sicca, vernal conjunctivitis, allergic rhinitis, autoimmune hematological disorders, hemolytic anemia, aplastic anemia, pure red cell aplasia, idiopathic thrombocytopenia, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener's granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic malabsorption syndrome, autoimmune inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, celiac disease, periodontitis, pulmonary hyaline disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine ophthalmopathy, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, primary biliary cirrhosis, and uveitis (anterior or posterior). Sjögren's syndrome, interstitial pulmonary fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, nephritis, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis, idiopathic nephrotic syndrome, minimal change nephropathy, chronic granulomatous disease, endometriosis, leptospirosis, glaucoma, retinal disease, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle wasting, catabolic disorders, obesity, fetal growth restriction, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, anhidrotic urticarial dysplasia, Behçet's disease, incontinentia pigmenti, Paget's disease, pancreatitis, hereditary periodic fever syndrome, asthma, acute lung injury, acute respiratory distress syndrome, eosinophilia, hypersensitivity, anaphylaxis, fibrosis, gastritis, gastroenteritis, sinusitis, ocular allergy, silica-induced disease, chronic obstructive pulmonary diseaseDiseases (COPD), cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuritis, cataracts, muscle inflammation associated with systemic sclerosis, inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease, lichen planus, appendicitis, atopic dermatitis, asthma, allergies, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic transplant rejection, colitis, conjunctivitis, cystitis, dacryodenitis, dermatitis, juvenile rheumatoid arthritis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, panentotitis, epicondylitis, epididymitis, fasciitis, Henoch-Schönlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, larynx Inflammation, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis media, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, urticaria, phlebitis, pneumonitis, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendinitis, tonsillitis, ulcerative colitis, vasculitis, vulvitis, These include alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity vasculitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, acquired epidermolysis bullosa, acute or chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, cryopyrin-associated periodic syndrome (CAPS), and osteoarthritis. In certain preferred embodiments, the inflammatory disease or disorder is hypercytokinemia. In certain embodiments, hypercytokinemia is induced by an infectious agent. In certain embodiments, the infectious agent is a virus. In certain preferred embodiments, the virus is a coronavirus (e.g., COVID-19). In other embodiments, the infectious agent is a bacterium. In certain embodiments, the inflammatory disease or disorder is graft-versus-host disease (GVHD). In certain embodiments, GVHD is chronic graft-versus-host disease.GVHD is a disease (cGVHD). In certain embodiments, GVHD is scleroderma GVHD, steroid-resistant GVHD, cyclosporine-resistant GVHD, GVHD, oral GVHD, reticular oral GVHD, erosive GVHD, or ulcerative oral GVHD. In certain embodiments, GVHD is scleroderma GVHD. In certain embodiments, GVHD is oral GVHD. In certain embodiments, GVHD is reticular oral GVHD. In certain embodiments, GVHD is erosive GVHD. In certain embodiments, GVHD is ulcerative oral GVHD. In certain embodiments, GVHD is overlapping chronic GVHD. In certain embodiments, GVHD is classic chronic GVHD. In certain embodiments, GVHD is steroid-resistant GVHD. In certain embodiments, GVHD is cyclosporine-resistant GVHD. In certain embodiments, GVHD is refractory. In certain embodiments, GVHD is recurrent.
[0050] In certain embodiments, the disease or disorder is resistant to treatment with a BTK inhibitor alone. In certain embodiments, the disease or disorder is resistant to treatment with a BTK inhibitor as monotherapy. In certain embodiments, the disease or disorder is resistant to treatment with ibrutinib, acalabrutinib, zanubrutinib, evobrutinib, ONO-4059, spebratinib, or HM7 1224. In certain preferred embodiments, the disease or disorder is resistant to treatment with ibrutinib.
[0051] In certain embodiments, the disease or disorder is related to chronic anemia. In certain embodiments, the disease or disorder is chronic anemia. In certain embodiments, the disease or disorder is related to transfusion dependence.
[0052] In certain embodiments, the subject is a human adult.
[0053] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally once daily at a dose of approximately 50 mg, and the disease or disorder is DLBCL. In a particular embodiment, the DLBCL is relapsing or refractory.
[0054] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally once daily at a dose of approximately 50 mg, and the disease or disorder is FL. In a particular embodiment, FL is relapsing or refractory.
[0055] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally once daily at a dose of approximately 300 mg, and the disease or disorder is WM. In a particular embodiment, WM is relapsing or refractory.
[0056] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally twice daily at a dose of approximately 50 mg, and the disease or disorder is DLBCL. In a particular embodiment, the DLBCL is relapsing or refractory.
[0057] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally twice daily at a dose of approximately 300 mg, and the disease or disorder is LPL. In a particular embodiment, LPL is relapsing or refractory.
[0058] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally twice daily at a dose of approximately 300 mg, and the disease or disorder is GCB DLBCL. In a particular embodiment, the GCB DLBCL is relapsing or refractory.
[0059] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally twice daily at a dose of approximately 400 mg, and the disease or disorder is ABC DLBCL. In a particular embodiment, the ABC DLBCL is relapsing or refractory.
[0060] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally twice daily at a dose of approximately 400 mg, and the disease or disorder is MZL. In a particular embodiment, MZL is relapsing or refractory.
[0061] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally twice daily at a dose of approximately 300 mg, and the disease or disorder is MZL. In a particular embodiment, MZL is relapsing or refractory.
[0062] In a particular embodiment, the IRAK4 inhibitor is compound 1, which is administered orally twice daily at a dose of approximately 300 mg, and the disease or disorder is MALT. In a particular embodiment, MALT is relapsing or refractory.
[0063] In certain embodiments, compound 1 is administered continuously (e.g., compound 1 is administered without rest days). In other embodiments, compound 1 is administered intermittently (e.g., compound 1 is administered continuously, interrupted by rest days of one or more days). In certain embodiments, each rest day lasts for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days. In certain preferred embodiments, the rest day lasts for 7 days. In even more preferred embodiments, compound 1 is administered daily for 3 weeks, followed by a 1-week rest period, optionally followed by 3 weeks of daily administration and a 1-week rest period, and this cycle may be repeated further. In certain embodiments, the aforementioned administration regimens are continued with alternating periods of administration and rest days until a change in disease status is observed (e.g., complete response, partial response, or unacceptable toxicity). A method for treating certain diseases and disorders using compound 1 is disclosed in PCT / U20S21 / 030192, the contents of which are fully incorporated herein by reference.
[0064] Previous treatment The methods disclosed herein may be used as first-line therapy or applied to patients who have not achieved a partial or complete response to one or more prior anticancer or anti-inflammatory therapies. In certain embodiments, the subject has previously received at least one anticancer therapy. In certain embodiments, the patient has previously received one anticancer therapy. In other embodiments, the patient has previously received two anticancer therapies. In yet another embodiment, the patient has previously received three anticancer therapies. In yet another embodiment, the patient has previously received four anticancer therapies. In yet another embodiment, the patient has previously received five anticancer therapies. In certain embodiments, at least one anticancer therapy is selected from anti-CD20 antibodies, nitrogen mustard, steroids, purine analogs, DNA topoisomerase inhibitors, DNA intercalators, tubulin inhibitors, BCL-2 inhibitors, proteasome inhibitors, Toll-like receptor inhibitors, kinase inhibitors, SRC kinase inhibitors, PI3K kinase inhibitors, BTK inhibitors, glutaminase inhibitors, PD-1 inhibitors, PD-L1 inhibitors, and methylating agents, or combinations thereof. In certain embodiments, the anticancer therapy is selected from ibrutinib, rituximab, bendamustine, bortezomib, dexamethasone, chlorambucil, cladribine, cyclophosphamide, doxorubicin, vincristine, venetoclax, ifosfamide, prednisone, oprozomib, ixazomib, acalabrutinib, zanubrutinib, IMO-08400, idelalisib, ambrelasib, CB-839, fludarabine, and thalidomide, or a combination thereof. In certain embodiments, the anticancer therapy is ibrutinib. In certain embodiments, the anticancer therapy is ibrutinib and rituximab. In certain embodiments, the anticancer therapy is bendamustine. In certain embodiments, the anticancer therapy is bendamustine and rituximab. In certain embodiments, the anticancer therapy is bortezomib. In certain embodiments, the anticancer therapy is bortezomib and dexamethasone. In certain embodiments, the anticancer therapy is bortezomib and rituximab. In certain embodiments, the anticancer therapy is bortezomib, rituximab, and dexamethasone.In certain embodiments, the anticancer therapy is chlorambucil. In certain embodiments, the anticancer therapy is cladribine. In certain embodiments, the anticancer therapy is cladribine and rituximab. In certain embodiments, the anticancer therapy is cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (i.e., CHOP-R). In certain embodiments, the anticancer therapy is cyclophosphamide, prednisone, and rituximab (i.e., CPR). In certain embodiments, the anticancer therapy is fludarabine. In certain embodiments, the anticancer therapy is fludarabine and rituximab. In certain embodiments, the anticancer therapy is fludarabine, cyclophosphamide, and rituximab. In certain preferred embodiments, the anticancer therapy is rituximab. In certain preferred embodiments, the anticancer therapy includes rituximab. In certain embodiments, the anticancer therapy is rituximab, cyclophosphamide, and dexamethasone (i.e., RCD). In certain embodiments, the anticancer therapy is thalidomide. In certain embodiments, the anticancer therapy is thalidomide and rituximab. In certain embodiments, the anticancer therapy is venetoclax. In certain embodiments, the anticancer therapy is cyclophosphamide, bortezomib, and dexamethasone (i.e., R-CyBorD). In certain embodiments, the anticancer therapy is a hypomethylating agent. In certain embodiments, the subject has previously received at least 6 cycles of a hypomethylating agent. In certain embodiments, the anticancer therapy is any combination of the above, for example, the subject may first receive rituximab and then at a later date receive a combination of rituximab, cyclophosphamide, and dexamethasone (i.e., RCD).
[0065] In certain embodiments, the subject has previously received at least one type of anti-inflammatory therapy. In certain embodiments, the patient has previously received one type of anti-inflammatory therapy. In other embodiments, the patient has previously received two types of anti-inflammatory therapy. In yet another embodiment, the patient has previously received three types of anti-inflammatory therapy. In yet another embodiment, the patient has previously received four types of anti-inflammatory therapy. In certain embodiments, the anti-inflammatory agent is a steroid (e.g., a corticosteroid). In certain embodiments, the anti-inflammatory therapy is hydrocortisone, cortisone, etamethasone neb, prednisone, prednisolone, triamcinolone, dexamethasone, or fludrocortisone, or a combination thereof.
[0066] The subject may also have received or be prepared for other non-chemotherapy treatments, such as surgery, radiation, or bone marrow transplantation. In certain embodiments, the subject has previously received etoposide chemo-mobilization therapy. In certain embodiments, the subject has previously received bone marrow transplantation. In certain embodiments, the subject has previously received stem cell transplantation. In certain embodiments, the subject has previously received autologous cell transplantation. In certain embodiments, the subject has previously received allogeneic stem cell transplantation. In certain embodiments, the subject has previously received hematopoietic stem cell transplantation. In certain embodiments, the subject has previously received carmustine, etoposide, cytarabine, and melphalan (i.e., BEAM conditioning). In certain embodiments, the subject has previously received reinduction therapy.
[0067] The subject may also have previously shown a favorable outcome compared to previous therapy, only requiring additional treatment at a later date. In certain embodiments, the subject has previously achieved a partial response. In certain embodiments, the subject has previously achieved a good partial response. In certain embodiments, the subject has previously achieved a complete response. In certain embodiments, the cancer is recurrent. In certain embodiments, the cancer is refractory.
[0068] The subject may also have one or more pre-existing or arising gene mutations that cause the subject's cancer to be more or less resistant to the therapy. In certain embodiments, the subject has a mutation in RICTOR. In certain embodiments, the subject has an N1065S mutation in RICTOR. In certain preferred embodiments, the subject has a mutation in MYD88. In certain even more preferred embodiments, the subject has an L265P mutation in MYD88. In certain embodiments, the subject has a mutation in TET2. In certain embodiments, the subject does not have a mutation in CXCR4. In other embodiments, the subject has a mutation in CXCR4. In certain embodiments, the subject exhibits early progression. In certain embodiments, the subject has not previously received a BTK inhibitor.
[0069] In certain embodiments, the subject achieves a partial response after administration of the compound. In certain embodiments, the subject achieves a good partial response after administration of the compound. In other embodiments, the subject achieves a complete response after administration of the compound. In certain embodiments, the subject achieves a partial response within 7 days of receiving the compound. In certain embodiments, the subject achieves a good partial response within 7 days of receiving the compound. In certain embodiments, the subject achieves a complete response within 7 days of receiving the compound. In certain embodiments, the tumor volume of the subject decreases by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%. In certain embodiments, the tumor volume of the subject decreases by 5%. In certain embodiments, the tumor volume of the subject decreases by 10%. In certain embodiments, the tumor volume of the subject decreases by 15%. In certain embodiments, the target tumor volume is reduced by 20%. In certain embodiments, the target tumor volume is reduced by 25%. In certain embodiments, the target tumor volume is reduced by 30%. In certain embodiments, the target tumor volume is reduced by 35%. In certain embodiments, the target tumor volume is reduced by 40%. In certain embodiments, the target tumor volume is reduced by 45%. In certain embodiments, the target tumor volume is reduced by 50%. In certain embodiments, the target tumor volume is reduced by 55%. In certain embodiments, the target tumor volume is reduced by 60%. In certain embodiments, the target tumor volume is reduced by 65%. In certain embodiments, the target tumor volume is reduced by 70%. In certain embodiments, the target tumor volume is reduced by 80%. In certain embodiments, the target tumor volume is reduced by 85%. In certain embodiments, the target tumor volume is reduced by 90%. In certain embodiments, the target tumor volume is reduced by 95%.
[0070] Method of performing immunohistochemical staining In certain embodiments of the methods of this disclosure, the expression level of NF-κB p-p50 in a sample can be determined by immunohistochemical staining. Methods for performing immunohistochemical staining are generally known to those skilled in the art. Briefly, a tissue sample is brought into contact with an antibody specific to NF-κB p-p50 or NF-κB p-p65. After an incubation period, the tissue sample is brought into contact with a secondary antibody. The secondary antibody recognizes and binds to the primary antibody. The secondary antibody may include a complexed activity (e.g., enzyme activity) used to detect the presence of the secondary antibody, and consequently the presence of the primary antibody, and consequently the presence of NF-κB p-p50 or NF-κB p-p65. Examples of complexed activities may be any known to those skilled in the art to be useful in creating a detectable immunohistochemical signal. Suitable complexing enzymes for secondary antibodies include, for example, horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and β-galactosidase, and fluorescent probes, radioisotopes, chemiluminescent compounds, bioluminescent compounds, or combinations thereof are also being considered.
[0071] In certain embodiments, the antibody specific to NF-κB p-p50 or NF-κB p-p65 is a commercially available NF-κB p-p50 antibody. In certain embodiments, the antibody specific to NF-κB p-p50 or NF-κB p-p65 is a polyclonal antibody. In certain embodiments, the antibody specific to NF-κB p-p50 or NF-κB p-p65 is a monoclonal antibody. In certain embodiments, the antibody specific to NF-κB p-p50 or NF-κB p-p65 is a rabbit antibody. In certain embodiments, the NF-κB p-p50 specific antibody is phospho-p50 NF-kappa B(Ser337)(sc-271908)Ab (supplied by Santa Cruz Biotechnology). In certain embodiments, the NF-κB p-p65 specific antibody is phospho-p65 NF-kappa B(Ser536)(ab86299)Ab (supplied from Abcam). In certain embodiments, the NF-κB p-p65 specific antibody is phospho-p65 NF-kappa B(Ser276)(ab194726)Ab (supplied from Abcam).
[0072] In certain embodiments, the secondary antibody is commercially available. In certain embodiments, the secondary antibody is goat anti-rabbit immunoglobulin conjugated with a peroxidase-labeled polymer (such as that contained in the EnVision+System-HRP kit (DAKO, Carpinteria, CA)).
[0073] In the method of this disclosure, after determining the expression level of NF-κB p-p50 or NF-κB p-p65 in a tissue sample, this level is compared to the expression level of NF-κB p-p50 in a reference sample. In certain embodiments, the reference sample is known to be of the same or equivalent tissue type as the tissue sample, but with normal or non-expression levels of NF-κB p-p50 or NF-κB p-p65. In certain embodiments, the reference sample is normal or non-infected tissue taken from an individual or population known to be of the same tissue type as the tissue sample, but with normal or non-expression levels of NF-κB p-p50 or NF-κB p-p65. In certain embodiments, the reference sample is normal or non-infected tissue taken from the same individual as the tissue sample, with the same or equivalent tissue type as the tissue sample. In certain embodiments, the reference sample includes a subpopulation of normal or unaffected cells in a tissue sample. In certain embodiments, the reference sample is a group of cells or tissues that do not exhibit a phenotype with elevated NF-κB p-p50 or NF-κB p-p65 expression levels.
[0074] Elevated expression levels are detected when the expression levels of NF-κB p-p50 or NF-κB p-p65 in a tissue sample are higher than those in a reference sample. Positive expression of NF-κB p-p50 or NF-κB p-p65 can be defined as more than 50% of cancer cells being stained positively in the cytoplasm and / or nucleus.
[0075] The immunohistochemical staining methods of this disclosure yield a biological sample. The biological sample may be any tissue specimen or any cell collection derived from tissue. The biological sample may be derived from any animal or human. In certain embodiments, the biological sample is of human origin. In other embodiments, the biological sample is of animal origin.
[0076] In the immunohistochemical staining method of this disclosure, a biological sample is contacted with a primary antibody specific to NF-κB p-p50 or NF-κB p-p65 to obtain a primary antibody-contacted biological sample. The primary antibody is specific to NF-κB p-p50, meaning that this antibody selectively binds to NF-κB p-p50 or NF-κB p-p65. In certain embodiments, the primary antibody is a polyclonal antibody. In certain embodiments, the primary antibody is a monoclonal antibody. In certain embodiments, the primary antibody is a rabbit polyclonal antibody. In certain embodiments, the primary antibody is a rabbit monoclonal antibody.
[0077] In the immunohistochemical staining method of this disclosure, a primary antibody-contact biological sample is contacted with a secondary antibody specific to the primary antibody, the secondary antibody also possessing complexed activity. The secondary antibody must selectively bind to the primary antibody. The secondary antibody may originate from the same species as the primary antibody or from a different species. The secondary antibody may be a polyclonal antibody or a monoclonal antibody.
[0078] Secondary antibodies also possess complexed activity, which may be enzymatic activity. In certain embodiments, the enzymatic activity is the intrinsic activity of the secondary antibody. In other embodiments, the enzymatic activity of the secondary antibody is given by an enzyme complexed with the antibody.
[0079] In certain embodiments, the enzymatic activity of the secondary antibody is peroxidase activity. In other embodiments, the enzymatic activity of the secondary antibody is alkaline phosphatase activity. Examples of complexed enzymatic activities may be any known to those skilled in the art to be useful for creating detectable immunohistochemical signals, such as horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and β-galactosidase. Other immunohistochemical signals may also be considered, such as fluorescent probes, radioisotopes, chemiluminescent compounds, bioluminescent compounds, or combinations thereof.
[0080] In the immunohistochemical staining method of this disclosure, the product obtained by contacting a primary antibody-contacted biological sample with a secondary antibody is one in which the primary antibody is bound to the biological sample and the secondary antibody is bound to this primary antibody. In the method of this disclosure, this product is contacted with a chromogenic substrate for the enzymatic activity of the secondary antibody.
[0081] The chromogenic substrate for the enzymatic activity of the secondary antibody is a compound that changes color upon reaction with the enzymatic activity of the secondary antibody. In certain embodiments, the chromogenic substrate is diaminobenzidine (DAB). In other embodiments, the chromogenic substrate is 3-amino-9-ethylcarbazole (AEC). In yet another embodiment, the chromogenic substrate is 5-bromo-4-chloro-3-indolyl phosphate / tetranitrobluetetrazolium (BCIP / TNBT). In yet another embodiment, the chromogenic substrate is naphthol AS-MX phosphate + Fast Blue BB.
[0082] After treating the sample with a chromogenic substrate, the product is counterstained for a certain period of time. Any counterstain that sufficiently brings out the color contrast of the chromogenic substrate can be used. Several different counterstains are known to those skilled in the art, and these include, for example, methyl green and hematoxylin.
[0083] In certain embodiments, the product is subsequently counterstained for up to 1 minute. In certain embodiments, the product is counterstained for up to 10 seconds.
[0084] In certain embodiments, the counterstain is hematoxylin. Methods of using hematoxylin are known to those skilled in the art. See, for example, Godwin Avwioro, Histochemical uses of Haematoxylin—A Review, JPCS Vol.1, April-June 2011, 24-34. The concentration of hematoxylin is generally about 1 g / L to about 2 g / L.
[0085] Pharmaceutical composition The compositions and methods of the present invention can be used to treat individuals in need of treatment. In certain embodiments, the individuals are mammals such as humans, or non-human mammals. When administered to animals such as humans, the compositions or compounds are preferably administered as a pharmaceutical composition comprising, for example, the compounds of the present invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents, or vehicles such as glycols or glycerols, oils such as olive oil, or injectable organic esters. In preferred embodiments, when such a pharmaceutical composition is for human administration, particularly for invasive administration routes (i.e., routes such as injection or transplantation that avoid transport or diffusion across the epithelial barrier), the aqueous solution is pyrogen-free or substantially pyrogen-free. Excipients can be selected, for example, to result in delayed release of the drug or to selectively target one or more cells, tissues, or organs. Pharmaceutical compositions may be in the form of dosage units such as tablets, capsules (including sprinkle capsules and gelatin capsules), granules, lyophilized reconstituters, powders, liquids, syrups, suppositories, and injections. Compositions may also be present in transdermal delivery systems, such as skin patches. Compositions may also be present in solutions suitable for topical administration, such as lotions, creams, or ointments.
[0086] A pharmaceutically acceptable carrier may include, for example, a physiologically acceptable agent that acts to stabilize, increase the solubility of, or increase the absorption of a compound, such as the compound of the present invention. Such physiologically acceptable agents include, for example, carbohydrates such as glucose, sucrose, or dextran; antioxidants such as ascorbic acid or glutathione; chelating agents; low molecular weight proteins; or other stabilizers or excipients. The selection of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition may be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical composition (preparation) may also be a liposome or other polymer matrix, in which, for example, the compound of the present invention can be incorporated. For example, liposomes containing phospholipids or other lipids are non-toxic, physiologically acceptable, and metabolizable carriers that are relatively easy to manufacture and administer.
[0087] The phrase "pharmaceutically acceptable" is used herein to mean a compound, material, composition, and / or dosage form that is suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems and complications, and that is commensurate with a reasonable benefit / risk ratio, within the bounds of sound medical judgment.
[0088] As used herein, the phrase “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be “acceptable” in the sense that it is compatible with the other components of the formulation and is not harmful to the patient. Some examples of materials that may function as pharmaceutically acceptable carriers are: (1) sugars, e.g., lactose, glucose, and sucrose; (2) starches, e.g., corn starch and potato starch; (3) cellulose and its derivatives, e.g., sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) tragacanth powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, e.g., cocoa butter and suppository wax; (9) oils, e.g., peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, and corn oil. (10) Glycols, such as propylene glycol, (11) Polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol, (12) Esters, such as ethyl oleate and ethyl laurate, (13) Agar, (14) Buffers, such as magnesium hydroxide and aluminum hydroxide, (15) Alginic acid, (16) Water free of pyrogens, (17) Isotonic saline, (18) Ringer's solution, (19) Ethyl alcohol, (20) Phosphate buffer, and (21) Other non-toxic, suitable substances used in pharmaceutical formulations.
[0089] Pharmaceutical compositions (preparations) can be administered to a target by any of a number of routes of administration, including, for example, oral (e.g., aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, and pastes for application to the tongue), absorption through the oral mucosa (e.g., sublingually), subcutaneously, transdermally (e.g., as a patch applied to the skin), and topically (e.g., as a cream, ointment, or spray applied to the skin). Compounds may also be prepared for inhalation. In certain embodiments, compounds may be simply dissolved or suspended in sterile water. Details of suitable administration routes and suitable compositions can be found, for example, in U.S. Patents 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970, and 4,172,896, and the patents cited herein.
[0090] The formulations can be conveniently presented in unit dosage forms and can be prepared by any method well known in the field of pharmacy. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form varies depending on the host being treated and the specific mode of administration. Generally, the amount of active ingredient that can be combined with a carrier material to produce a single dosage form is the amount of the compound that produces the therapeutic effect. Generally, out of 100 percent, this amount is in the range of about 1 percent to about 99 percent of the active ingredient, preferably about 5 percent to about 70 percent, and most preferably about 10 percent to about 30 percent.
[0091] Methods for preparing these formulations or compositions include the step of combining an active compound, such as the compound of the present invention, with a carrier and optionally one or more auxiliary components. Generally, formulations are prepared by uniformly and closely combining the compound of the present invention with a liquid carrier or a finely divided solid carrier, or both, and then optionally shaping the product.
[0092] Formulations of the present invention suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavoring base, usually sucrose and acacia or tragacanth), lyophilized agents, powders, granules, or liquids or suspensions in aqueous or non-aqueous liquids, or oil-in-water or water-in-oil emulsions, or licks or syrups, or lozenges (using an inert base, e.g., gelatin and glycerin, or sucrose and acacia), and / or mouthwashes, each containing a predetermined amount of the compound of the present invention as an active ingredient. Compositions or compounds may also be administered as boluses, licks or pastes.
[0093] To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, sugar-coated tablets, powders, granules, etc.), the active ingredient is mixed with one or more pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or bulking agents, e.g., starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, e.g., carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants, e.g., glycerol; (4) (5) Disintegrants, e.g., agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (6) Dissolution retarders, e.g., paraffin; (7) Absorption enhancers, e.g., quaternary ammonium compounds; (8) Wetting agents, e.g., cetyl alcohol and glycerol monostearate; (9) Absorbents, e.g., kaolin and bentonite clay; (10) Lubricants, e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; (11) Complexing agents, e.g., modified and unmodified cyclodextrins; and (12) Colorants. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical composition may also contain buffers. Similar types of solid compositions can also be used as fillers for soft and hard-filled gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycol.
[0094] Tablets can be prepared by compression or molding, using one or more optional auxiliary components. Compressed tablets can be prepared using a binder (e.g., gelatin or hydroxypropyl methylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate or cross-linked carboxymethylcellulose sodium), a surfactant, or a dispersant. Wet tablets can be prepared by molding a mixture of powder compounds moistened with an inert liquid diluent using appropriate machinery.
[0095] Other solid dosage forms of pharmaceutical compositions, such as tablets, sugar-coated tablets, capsules (including sprinkle capsules and gelatin capsules), pills, and granules, may optionally be prepared with score lines or coatings and shells, such as enteric coatings and other coatings known in the pharmaceutical formulation field. They may also be prepared to provide sustained or controlled release of the active ingredient therein, for example, using oxypropylmethylcellulose, other polymer matrices, liposomes, and / or microspheres in various ratios to yield a desired release profile. They may be sterilized, for example, by filtration with a bacterial-retaining filter or by incorporating a sterilizer in the form of a sterile solid composition that can be dissolved in sterile water or other sterile injection medium immediately before use. These compositions may also optionally contain opacifiers, which may optionally release the active ingredient only, or preferentially, in a delayed manner in a specific part of the gastrointestinal tract. Examples of usable embedding compositions include polymers and waxes. The active ingredient may also be in microencapsulated form together with one or more of the above excipients, where appropriate.
[0096] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophilized reconstituted emulsions, microemulsifies, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, liquid dosage forms may include inert diluents commonly used in the art, such as water or other solvents, cyclodextrins and their derivatives, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed, peanut, corn, germ, olive, castor oil, sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, as well as mixtures thereof.
[0097] In addition to inert diluents, oral compositions may also contain auxiliary agents such as humectants, emulsifiers and suspending agents, sweeteners, flavorings, colorants, fragrances and preservatives.
[0098] In addition to the active compound, the suspension may include suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, metahydroxyaluminum, bentonite, agar and tragacanth, and mixtures thereof.
[0099] Dosage forms for topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and any preservatives, buffers, or propellants as needed.
[0100] Ointments, pastes, creams, and gels may contain excipients such as animal and plant fats and physical fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, talc, and zinc oxide, or mixtures thereof, in addition to the active compound.
[0101] Powders and sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures thereof, in addition to the active compound. Sprays may also contain conventional propellants such as chlorofluorohydrocarbons, as well as volatile unsubstituted hydrocarbons such as butane and propane.
[0102] Transdermal patches offer the additional advantage of providing controlled delivery of the compounds of the present invention to the body. Such dosage forms can be prepared by dissolving or dispersing the active compound in a suitable medium. Absorption enhancers can also be used to increase the flow of the compound across the skin. The velocity of such a flux can be controlled by providing a velocity-controlled membrane or by dispersing the compound in a polymer matrix or gel.
[0103] As used herein, the phrases “parenteral administration” and “administered parenterally” typically refer to modes of administration other than enteral and topical administration by injection, and include, but are not limited to, intravenous, intramuscular, intra-arterial, subarachnoid, intrathecal, intracystic, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, intraspinal, and intrasternal injections and infusions. Pharmaceutical compositions suitable for parenteral administration include one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions, or emulsions, or one or more active compounds in combination with a sterile powder, which may be reconstituted into a sterile injection solution or dispersion immediately before use, and may contain antioxidants, buffers, bacteriostatic agents, solutes that make the formulation isotonic with the blood or suspension or thickener of the recipient of the intended purpose.
[0104] Suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (such as glycerol, propylene glycol, and polyethylene glycol), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Appropriate fluidity can be maintained, for example, by using coating materials such as lecithin, maintaining the particle size required in the case of dispersions, and using surfactants.
[0105] These compositions may also contain auxiliary agents such as preservatives, humectants, emulsifiers, and dispersants. Prevention of microbial action can be ensured by including various antimicrobial and antifungal agents, such as parabens, chlorobutanol, and phenolsorbic acid. It may also be desirable to include isotonic agents such as sugars and sodium chloride in the composition. Furthermore, sustained absorption of injectable dosage forms can be achieved by including absorption-delaying agents such as aluminum monostearate and gelatin.
[0106] In some cases, it is desirable to slow down the absorption of a drug from subcutaneous or intramuscular injection in order to maintain the drug's effect. This can be achieved by using a liquid suspension of a crystalline or amorphous material with low water solubility. The absorption rate of the drug then depends on its dissolution rate, which in turn may depend on the crystal size and crystal form. Alternatively, delayed absorption of a parenterally administered drug form can be achieved by dissolving or suspending the drug in an oily vehicle.
[0107] Injectable depot formulations are prepared by forming a microencapsulation matrix of the target compound with biodegradable polymers such as polylactide-polyglycolide. The rate of drug release can be controlled depending on the ratio of drug to polymer and the properties of the specific polymer used. Other examples of biodegradable polymers include poly(orthoester) and poly(anhydride). Depot-injectable formulations are also prepared by encapsulating the drug in liposomes or microemulsifies that are compatible with body tissues.
[0108] For use in the method of the present invention, the active compound can be provided by itself or, for example, in combination with a pharmaceutically acceptable carrier as a pharmaceutical composition containing 0.1 to 99.5% (more preferably 0.5 to 90%) of the active ingredient.
[0109] The delivery method may also be provided by refillable or biodegradable devices. In recent years, various sustained-release polymer devices have been developed and tested in vivo for the controlled delivery of drugs, including protein-based biopharmaceuticals. Various biocompatible polymers (including hydrogels), encompassing both biodegradable and non-biodegradable polymers, can be used to form implants for the sustained release of compounds at specific target sites.
[0110] The actual dosage level of the active ingredient in a pharmaceutical composition can be modified to obtain an effective amount of the active ingredient that achieves the therapeutic response, composition, and mode of administration for a particular patient without causing toxicity to the patient.
[0111] The selected dosage level depends on a variety of factors, including those well known in the medical field, such as the activity of the specific compound or combination of compounds used, or their esters, salts, or amides; the route of administration; the time of administration; the elimination rate of the specific compound used; the duration of treatment; other drugs, compounds, and / or substances used in combination with the specific compound used; and the age, sex, weight, condition, general health status, and medical history of the patient being treated.
[0112] A physician or veterinarian with ordinary skill in the art can easily determine and prescribe the required therapeutically effective dose of a pharmaceutical composition. For example, a physician or veterinarian can start with a dose of the pharmaceutical composition or compound at a level lower than the level required to achieve the desired therapeutic effect and gradually increase the dose until the desired effect is achieved. "Therapeutically effective dose" means a concentration of the compound sufficient to produce the desired therapeutic effect. It is generally understood that the effective dose of a compound varies depending on the subject's weight, sex, age, and medical history. Other factors that affect the effective dose include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the compound, and, if desired, other types of therapeutic agents administered with the compound of the present invention. Multiple administrations of the drug can deliver many total doses. Methods for determining efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison's Principles of Internal Medicine 13 ed., 1814-1882, incorporated herein by reference).
[0113] Generally, the appropriate daily dose of the active compound used in the compositions and methods of the present invention is the amount of the compound that is the minimum effective dose to produce a therapeutic effect. Such an effective dose generally depends on the factors mentioned above.
[0114] If necessary, the effective daily dose of the active compound may be administered as one, two, three, four, five, or six or more subdoses, optionally administered separately in unit dosage forms at appropriate intervals throughout the day. In certain embodiments of the present invention, the active compound may be administered twice or three times daily. In preferred embodiments, the active compound is administered once daily.
[0115] Patients receiving this treatment are any animal in need of treatment, including primates, especially humans; as well as other mammals, such as horses, cattle, pigs, sheep, cats, and dogs; poultry; and common pets.
[0116] In certain embodiments, the compounds of the present invention may be used alone or in combination with other types of therapeutic agents.
[0117] This disclosure includes the use of pharmaceutically acceptable salts of the compounds of the present invention in compositions and methods of the present invention. In certain embodiments, the salts intended for the present invention include, but are not limited to, alkyl, dialkyl, trialkyl, or tetraalkylammonium salts. In certain embodiments, the salts intended for the present invention include, but are not limited to, L-arginine, venentamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydravamin, 1H-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, 1-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In certain embodiments, the salts intended for the present invention include, but are not limited to, Na, Ca, K, Mg, Zn, or other metal salts.In certain embodiments, the salts intended for use in the present invention include 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, l-ascorbic acid, l-aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecyl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, and d-glucohep. Examples include, but are not limited to, tonic acid, d-gluconic acid, d-glucuronic acid, glutamic acid, glutaric acid, glycerophosphate, glycolic acid, hypric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, l-malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, l-pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, l-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, and undecylenate.
[0118] pharmaceutically acceptable acid addition salts can also exist as various solvates with water, methanol, ethanol, dimethylformamide, and the like. Mixtures of such solvates can also be prepared. The source of such solvates may be from the crystallization solvent, inherent to the preparation or crystallization solvent, or exogenous to such solvent.
[0119] Wetting agents such as sodium lauryl sulfate and magnesium stearate, emulsifiers and lubricants, as well as colorants, release agents, coating agents, sweeteners, flavorings and fragrances, preservatives and antioxidants may also be present in the composition.
[0120] Examples of pharmaceutically acceptable antioxidants include (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, and sodium sulfite; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, and alpha-tocopherol; and (3) metal chelating agents, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, and phosphoric acid.
[0121] definition Unless otherwise defined herein, scientific and technical terms used in this application shall have meanings generally understood by those of an ordinary skill in the art. Generally, the nomenclature and techniques used in relation to chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics, and protein and nucleic acid chemistry as described herein are well known and commonly used in the art.
[0122] The methods and techniques described herein are generally well known in the art unless otherwise indicated, and are carried out in accordance with the conventional methods described in various general and more specific references cited and discussed throughout this specification. See, for example, “Principles of Neural Science,” McGraw-Hill Medical, New York, NY (2000); Motulsky, “Intuitive Biostatistics,” Oxford University Press, Inc. (1995); Lodish et al., “Molecular Cell Biology, 4th ed.”, WH Freeman & Co., New York (2000); Griffiths et al., “Introduction to Genetic Analysis, 7th ed.”, WH Freeman & Co., NY (1999); and Gilbert et al., “Developmental Biology, 6th ed.”, Sinauer Associates, Inc., Sunderland, MA (2000).
[0123] Chemical terms used herein, unless otherwise defined, are used in accordance with the customary usage of the art, as exemplified by “The McGraw-Hill Dictionary of Chemical Terms”, Parker S., Ed., McGraw-Hill, San Francisco, CA (1985).
[0124] All of the foregoing, and any other publications, patents, and published patent applications referenced herein, are incorporated herein by reference. In case of any conflict, this specification, including specific definitions, shall prevail.
[0125] The term “agent” is used herein to refer to compounds (such as organic or inorganic compounds, mixtures of compounds), biological macromolecules (such as nucleic acids, antibodies, parts thereof, and humanized, chimeric, and human antibodies and monoclonal antibodies, proteins or parts thereof, e.g., peptides, lipids, carbohydrates), or extracts made from biological materials such as cells or tissues of bacteria, plants, fungi, or animals (especially mammals). Agents include, for example, agents with known structures and agents with unknown structures. The ability of such agents to inhibit or promote AR degradation may make them suitable as “therapeutic agents” in the methods and compositions of this disclosure.
[0126] The terms "patient," "subject," or "individual" are used interchangeably and refer to either a human or a non-human animal. These terms include mammals such as humans, primates, livestock (including cattle and pigs), companion animals (e.g., dogs and cats), and rodents (e.g., mice and rats).
[0127] "Treating" a condition or patient means taking measures to obtain beneficial or desirable outcomes, including clinical outcomes. Beneficial or desirable clinical outcomes may include, but are not limited to, relief or improvement of one or more symptoms or conditions, whether detectable or undetectable; a reduction in the severity of the disease; a stable (i.e., non-worsening) state of the disease; prevention of disease progression; delay or slowing of disease progression; improvement or temporary relief of the condition; and remission (partial or complete remission). "Treatment" may also mean extending survival compared to the survival expected without treatment.
[0128] The term “prevent” is recognized in the art and is well understood in the art when used in relation to conditions such as local recurrence (e.g., pain), diseases such as cancer, complex syndromes such as heart failure, or any other medical condition, and includes the administration of a composition that reduces the frequency of symptoms of a medical condition in a subject or delays the onset of the condition compared to a subject who does not receive the composition. Thus, cancer prevention includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving prophylactic treatment compared to an untreated control population, and / or delaying the appearance of detectable cancerous growths in the treated population by a statistically and / or clinically significant amount compared to an untreated control population.
[0129] The "administration" or "delivery" of a substance, compound, or drug to a target can be carried out using one of the various methods known in the art. For example, a compound or drug can be administered intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, orally, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through the skin canal). The compound or drug can also be appropriately introduced by refillable or biodegradable polymer devices or other devices, e.g., patches and pumps, or formulations that provide sustained, sustained-release, or controlled release of the compound or drug. Deliveries can also be carried out, for example, once, multiple times, and / or over a period of time longer than one.
[0130] Appropriate methods for administering a substance, compound, or drug to a subject also depend, for example, on the subject's age and / or physical condition, as well as the chemical and biological properties of the compound or drug (e.g., solubility, digestibility, bioavailability, stability, and toxicity). In certain embodiments, the compound or drug is administered orally, for example, by ingestion. In certain embodiments, the orally administered compound or drug is in the form of a sustained-release or sustained-release formulation, or is administered using a device for such sustained-release or sustained-release.
[0131] As used herein, the phrase “co-administration” refers to any form of administration of two or more different therapeutic agents such that a second agent is administered while a previously administered therapeutic agent is still effective in the body (for example, the two agents may be effective for the patient simultaneously and may involve a synergistic effect between the two agents). For example, different therapeutic compounds may be administered simultaneously or sequentially, in the same formulation or in separate formulations. Thus, an individual receiving such treatment may benefit from the combined effect of different therapeutic agents.
[0132] The "therapeutic dose" or "therapeutic effective dose" of a drug or medication is the amount of the drug or medication that, when administered to a subject, produces the intended therapeutic effect. Complete therapeutic effect does not necessarily occur with a single dose, but may only occur after a series of doses. Therefore, the therapeutic dose may be administered in one or more doses. The exact effective dose required by the subject depends, for example, on the subject's size, health, and age, as well as the nature and severity of the condition being treated, such as cancer or MDS. Those skilled in the art can easily determine the effective dose for a given situation through routine experimentation.
[0133] Where used herein, the terms “optional” or “optionally” mean that the events or circumstances described below may or may not occur, and the descriptions include both cases in which the events or circumstances occur and cases in which they do not. For example, “optionally substituted alkyl” means both cases in which the alkyl can be substituted and cases in which the alkyl is not substituted.
[0134] Those skilled in the art will understand that substituents and substitution patterns for the compounds of the present invention can be selected so as to obtain chemically stable compounds that can be readily synthesized from readily available starting materials using methods known in the art and the methods described later. When a substituent itself is substituted with multiple groups, these multiple groups may be located on the same carbon or on different carbons, as long as a stable structure is ultimately obtained.
[0135] As used herein, the term “optionally substituted” means that one to six hydrogen radicals in a given structure are replaced by radicals of a particular substituent, such substituents include, but are not limited to, hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH2-O-alkyl, -OP(O)(O-alkyl)2, or -CH2-OP(O)(O-alkyl)2. Preferably, “optionally substituted” means that one to four hydrogen radicals in a given structure are replaced by the substituents described above. More preferably, one to three hydrogen radicals are replaced by the substituents described above. It will be understood that substituents may be further substituted.
[0136] As used herein, the term "alkyl" refers to a saturated aliphatic group, and such saturated aliphatic groups include, but are not limited to, C1-C 10 Linear alkyl groups or C1-C 10 Branched alkyl groups are included. Preferably, the "alkyl" group refers to a C1-C6 linear alkyl group or a C1-C6 branched alkyl group. Most preferably, the "alkyl" group refers to a C1-C4 linear alkyl group or a C1-C4 branched alkyl group. Examples of "alkyl" include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, 1-hexyl, 2-hexyl, 3-hexyl, 1-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 1-octyl, 2-octyl, 3-octyl, or 4-octyl, and the like. The "alkyl" group may be optionally substituted.
[0137] The term "acyl" is recognized in the relevant technical field and refers to a group represented by the general formula hydrocarbyl C(O)-, preferably alkyl C(O)-.
[0138] The term "acylamino" is recognized in the relevant technical field and refers to an amino group substituted with an acyl group, which can be represented, for example, by the formula hydrocarbyl C(O)NH-.
[0139] The term "acyloxy" is recognized in the relevant technical field and refers to a group represented by the general formula hydrocarbyl C(O)O-, preferably alkyl C(O)O-.
[0140] The term "alkoxy" refers to an alkyl group that has an added oxygen atom. Typical alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy, and similar groups.
[0141] The term "alkoxyalkyl" refers to an alkyl group substituted with an alkoxy group and can be represented by the general formula alkyl-O-alkyl.
[0142] The term "alkyl" refers to a saturated aliphatic group, which includes linear alkyl groups, branched alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups. In preferred embodiments, linear alkyl or branched alkyl groups have 30 or fewer carbon atoms in their skeleton (for example, C for linear groups). 1-30 Regarding branched chains, C 3-30 ), more preferably having 20 or fewer carbon atoms.
[0143] Furthermore, the term “alkyl” as used herein, in the examples and in the claims is intended to include both unsubstituted alkyl groups and substituted alkyl groups, the latter of which refer to alkyl moieties having substituents that replace hydrogens on one or more carbons of a hydrocarbon skeleton, such alkyl moieties include haloalkyl groups (such as trifluoromethyl and 2,2,2-trifluoroethyl).
[0144] "C x-y " or "C x -Cy The term "alkyl," when used with a chemical part (such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy), is intended to refer to a group containing x to y carbon atoms in the chain. C0 alkyl indicates hydrogen when the group is at a terminal position and a bond when the group is internal. 1-6 Alkyl groups, for example, contain 1 to 6 carbon atoms in their chain.
[0145] As used herein, the term "alkylamino" refers to an amino group substituted with at least one alkyl group.
[0146] As used herein, the term "alkylthio" refers to a thiol group substituted with an alkyl group, which can be represented by the general formula alkylS-.
[0147] The term "amide" as used herein refers to [ka] This refers to the basis, In the formula, R 9 and R 10 Each of these independently represents a hydrogen atom or a hydrocarbyl group, or R together with the N atom to which it is attached. 9 and R 10 This completes a heterocycle containing 4 to 8 atoms in the ring structure.
[0148] The terms "amine" and "amino" are recognized in the art, and include both unsubstituted and substituted amines, as well as their salts (e.g., [ka] This refers to the part that can be represented by, In the formula, R 9 , R 10 , and R 10 Each of the ' represents either a hydrogen atom or a hydrocarbyl group, and together with the N atom to which it is attached, it forms the R group. 9 and R10 This completes a heterocycle containing 4 to 8 atoms in the ring structure.
[0149] As used herein, the term "aminoalkyl" refers to an alkyl group substituted with an amino group.
[0150] As used herein, the term "aralkyl" refers to an alkyl group substituted with an aryl group.
[0151] As used herein, the term “aryl” includes substituted or unsubstituted monocyclic aromatic groups in which each atom of the ring is carbon. Preferably, the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, at least one of which rings is aromatic, and for example, the other cyclic rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
[0152] The term "carbamate" is recognized in the relevant technical field. [ka] This refers to the basis, In the formula, R 9 and R 10 This independently represents a hydrogen atom or a hydrocarbyl group.
[0153] As used herein, the term "carbocykrylalkyl" refers to an alkyl group substituted with a carbocyclic group.
[0154] The term "carbocyclic ring" includes monocyclic rings with 5 to 7 members and bicyclic rings with 8 to 12 members. Each ring in a bicyclic carbocyclic ring may be selected from saturated, unsaturated, and aromatic rings. A carbocyclic ring includes a bicyclic molecule in which one, two, three, or more atoms are shared between two rings. The term "condensed carbocyclic ring" refers to a bicyclic carbocyclic ring in which each ring shares two adjacent atoms with the other ring. Each ring in a condensed carbocyclic ring may be selected from saturated, unsaturated, and aromatic rings. In one embodiment, an aromatic ring (e.g., phenyl) may be condensed with a saturated or unsaturated ring (e.g., cyclohexane, cyclopentane, or cyclohexene). Any combination of saturated bicyclic rings, unsaturated bicyclic rings, and aromatic bicyclic rings is included in the definition of a carbocyclic ring, insofar as the bond valency allows. Examples of "carbocyclic rings" include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octa-3-ene, naphthalene, and adamantane. Examples of condensed carbocyclic rings include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-1H-indene, and bicyclo[4.1.0]hepta-3-ene. In a "carbocyclic ring," any one or more positions that could potentially contain a hydrogen atom may be substituted.
[0155] As used herein, the term "carbocykrylalkyl" refers to an alkyl group substituted with a carbocyclic group.
[0156] The term "carbonate" is recognized in the relevant technical field and refers to the group -OCO2-.
[0157] As used herein, the term "carboxyl" refers to a group represented by the formula -CO2H.
[0158] The term "cycloalkyl" includes substituted or unsubstituted non-aromatic monocyclic structures, preferably 4- to 8-membered rings, more preferably 4- to 6-membered rings. The term "cycloalkyl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, at least one of which rings is cycloalkyl, and the cycloalkyl ring has substituents (e.g., R 100 A ) is added. For example, other cyclic rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, denzodioxane, tetrahydroquinoline, and the like.
[0159] As used herein, the term "ester" refers to -C(O)OR 9 This refers to the base, R 9 This represents a hydrocarbyl group.
[0160] As used herein, the term “ether” refers to a hydrocarbyl group linked to another hydrocarbyl group via oxygen. Therefore, the ether substituent of a hydrocarbyl group can be hydrocarbyl-O-. Ethers can be symmetric or asymmetric. Examples of ethers, but not limited to, include heterocyclic-O-heterocyclic and aryl-O-heterocyclic groups. Ethers may contain an “alkoxyalkyl” group, which can be represented by the general formula alkyl-O-alkyl.
[0161] As used herein, the terms "halo" and "halogen" mean halogens, including chloro, fluoro, bromo, and iodine.
[0162] As used herein, the terms "hetaralkyl" and "heteroaralkyl" refer to alkyl groups substituted with hetaralkyl groups.
[0163] The terms “heteroaryl” and “hetalil” include substituted or unsubstituted aromatic monocyclic structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, the ring structure of such rings containing at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably 1 or 2 heteroatoms. The terms “heteroaryl” and “hetalil” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, at least one of which rings is heteroaromatic, for example, the other cyclic rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and similar groups.
[0164] As used herein, the term “heteroatom” means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.
[0165] As used herein, the term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclic group.
[0166] The terms "heterocyclyl", "heterocycle", and "heterocyclic" refer to a substituted or unsubstituted non-aromatic ring structure, preferably a 3- to 10-membered ring, more preferably a 3- to 7-membered ring, and the ring structure of such rings contains at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably 1 or 2 heteroatoms. The terms "heterocyclyl" and "heterocyclic" also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, and at least one of these rings is heterocyclic. For example, the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactone, lactam, and the like.
[0167] As used herein, the term "hydrocarbyl" refers to a group bonded through a carbon atom having no =O substituent or =S substituent, typically having at least one carbon-hydrogen bond and a primary carbon skeleton, but optionally may contain heteroatoms. Thus, groups such as methyl, ethoxyethyl, 2-pyridyl, and even trifluoromethyl are considered hydrocarbyl for the purposes of this application, but substituents such as acetyl (having an =O substituent on the linking carbon) and ethoxy (linked through oxygen rather than carbon) are not. Hydrocarbyl groups include, but are not limited to, aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
[0168] As used herein, the term "hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group.
[0169] The term "lower", when used with a chemical moiety (such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy), means a group having 10 or fewer, preferably 6 or fewer, atoms in the substituent. "Lower alkyl" refers to, for example, an alkyl group having 10 or fewer, preferably 6 or fewer, carbon atoms. In certain embodiments, an acyl substituent, acyloxy substituent, alkyl substituent, alkenyl substituent, alkynyl substituent, or alkoxy substituent as defined herein is a lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether used alone or in combination with other substituents (such as in the description of hydroxyalkyl and aralkyl, where, for example, when counting the number of carbon atoms in the alkyl substituent, the atoms in the aryl group are not counted).
[0170] The terms "polysicryl", "polycle", and "polycyclic" refer to two or more rings (such as cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl) in which two or more atoms are common to two adjacent rings, for example, such rings are "fused rings". Each of the polycyclic rings can be either substituted or unsubstituted. In certain embodiments, the number of atoms in each polycyclic ring is 3 to 10, preferably 5 to 7.
[0171] The term "sulfate" is recognized in the art and refers to the group -OSO3H or a pharmaceutically acceptable salt thereof.
[0172] The term "sulfonamide" is recognized in the art,
Chemical formula
[0173] The term "sulfoxide" is recognized in the relevant technical field and refers to the group -S(O)-.
[0174] The term "sulfonate" is recognized in the relevant technical field and refers to the SO3H group or its pharmaceutically acceptable salts.
[0175] The term "sulfone" is recognized in the relevant technical field and refers to the group -S(O)2-.
[0176] The term "substituted" refers to a moiety having a substituent that replaces hydrogen on one or more carbons of a backbone. "Substituted" or "substituted with" is understood to include the implicit condition that such substitution is in accordance with the allowable bonding valences of the atoms being substituted and the substituents, and that the substitution results in a stable compound (i.e., one in which conversions such as rearrangement, cyclization, elimination, etc. do not occur spontaneously). As used herein, the term "substituted" is intended to include all permissible substituents of organic compounds. In a broad aspect, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic organic compound substituents. Permissible substituents can be one or more and can be the same or different for a suitable organic compound. For the purposes of the present invention, a heteroatom (such as nitrogen) can have a hydrogen substituent and / or any of the permissible organic compound substituents described herein that satisfy the valence of the heteroatom. Substituents can include any of the substituents described herein, and such substituents can be, for example, halogen, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (such as thioester, thioacetate, or thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amide, amidine, imine, cyano, nitro, azide, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamide, sulfonyl, heterocyclyl, aralkyl, or an aromatic moiety or heteroaromatic moiety. One of ordinary skill in the art will understand that a moiety substituted on a hydrocarbon chain can itself be substituted, where appropriate.
[0177] As used herein, the term "thioalkyl" refers to an alkyl group substituted with a thiol group.
[0178] As used herein, the term "thioester" refers to a -C(O)SR 9 or -SC(O)R 9 group, wherein R 9 represents a hydrocarbyl.
[0179] As used herein, the term "thioether" is equivalent to "ether," in which oxygen is replaced by sulfur.
[0180] The term "urea" is recognized in the relevant technical field. [ka] It can be expressed by the following general formula: In the formula, R 9 and R 10 This independently represents hydrogen or hydrocarbyl.
[0181] As used herein, the term “modulate” includes inhibition or suppression of function or activity (such as cell proliferation), as well as enhancement of function or activity.
[0182] The phrase "pharmaceutically acceptable" is recognized in the art. In certain embodiments, this term includes compositions, excipients, adjuvants, polymers and other materials and / or dosage forms that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions or other problems and complications, and that are commensurate with a reasonable benefit / risk ratio, within the bounds of sound medical judgment.
[0183] "Pharmacologically acceptable salt" or "salt" is used herein to mean an acid addition salt or basic addition salt that is suitable or suitable for the treatment of a patient.
[0184] As used herein, the term "pharmaceutically acceptable acid addition salt" means any non-toxic organic or inorganic salt of any basic compound represented by Formula 1. Exemplary inorganic acids that form suitable salts include hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, as well as metal salts such as sodium hydrogen orthophosphate and potassium hydrogen sulfate. Exemplary organic acids that form suitable salts include monocarboxylic acids, dicarboxylic acids, and tricarboxylic acids such as glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, benzoic acid, phenylacetic acid, cinnamic acid, and salicylic acid, as well as sulfonic acids such as p-toluenesulfonic acid and methanesulfonic acid. Either monoacid salts or diacid salts can be formed, and such salts can exist in either a hydrated, solvated, or substantially anhydrous form. In general, the acid addition salts of the compounds of Formula 1 are soluble in water and various hydrophilic organic solvents and generally exhibit a higher melting point compared to their free base forms. The selection of suitable salts is known to those skilled in the art. Other non-pharmaceutically acceptable salts, such as oxalates, can be used in the isolation of the compounds of Formula 1, for example, for laboratory use or for subsequent conversion to pharmaceutically acceptable acid addition salts.
[0185] As used herein, the term "pharmaceutically acceptable basic addition salt" means any non-toxic organic or inorganic base addition salt of any acid compound represented by Formula 1 or any of their intermediates. Exemplary inorganic bases that form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide. Exemplary organic bases that form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as methylamine, trimethylamine, and picoline or ammonia. The selection of suitable salts is known to those skilled in the art.
[0186] Many of the compounds useful in the methods and compositions of this disclosure have at least one chiral center in their structure. This chiral center may be in an R or S configuration, and the R and S notation is used in accordance with the rules set out in Pure Appl. Chem. (1976), 45, 11-30. This disclosure intends all stereoisomers (enantiomers and diastereomers of compounds, salts, prodrugs, or mixtures thereof) (including all possible mixtures of stereoisomers). See, for example, WO01 / 062726.
[0187] Furthermore, certain compounds containing an alkenyl group may exist as Z (tuzamen) or E (entgegen) isomers. In each case, this disclosure includes both mixtures and separate individual isomers.
[0188] Some compounds may also exist in tautomer form. Such forms, though not explicitly shown in the formulas described herein, are intended to be included within the scope of this disclosure.
[0189] A “prodrug” or “pharmaceutically acceptable prodrug” refers to a compound that, after administration, is metabolized (e.g., hydrolyzed or oxidized) in a host to form a compound of the Disclosure (e.g., a compound of formula I). Typical examples of prodrugs include compounds having a biologically unstable or cleavable (protecting) group on the functional group of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, reverse hydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce an active compound. Examples of prodrugs using esters or phosphoramides as biologically unstable or cleavable (protecting) groups are disclosed in U.S. Patents 6,875,751, 7,585,851, and 7,964,580, the disclosures of which are incorporated herein by reference. The prodrugs of the Disclosure are metabolized to produce compounds of formula I. The Disclosure, to its extent, includes prodrugs of the compounds described herein. Standard procedures for selecting and preparing appropriate prodrugs are described, for example, in “Design of Prodrugs” Ed. H. Bundgaard, Elsevier, 1985.
[0190] As used herein, the phrase “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filter, diluent, excipient, solvent, or encapsulating material, that is useful for preparing a drug for medicinal or therapeutic use.
[0191] As used herein, the terms “logarithm of solubility,” “LogS,” or “logS” are used in the art to quantify the water solubility of a compound. The water solubility of a compound significantly affects its absorption and distribution characteristics. Low solubility often results in insufficient absorption. The LogS value is the unit strip logarithm (base 10) of solubility measured in mol / liter.
[0192] As used herein, the term “expression level” refers to the level and / or abundance of an expression product in a sample. For example, the expression level of a protein may be measured by staining a tissue sample (e.g., multiple cells) and measuring the abundance (i.e., frequency) and / or level of the protein across one or more cells (preferably multiple cells) in the tissue or across the tissue sample as a whole. [Examples]
[0193] The present invention will be described in general terms here, but will be more readily understood by referring to the following examples, which are included solely for illustrative purposes of specific aspects and embodiments of the invention and are not intended to limit the invention.
[0194] Example 1: Example of a method for determining the expression of NF-κB p-p50 or NF-κB p-p65 Formalin-fixed, paraffin-embedded sections of human tonsils and lymphomas were used. Tissue sections (5 μm) were deparaffinized and antigen retrieval was performed in citrate buffer at 90–100°C for 10–40 minutes. The sections were incubated in 1% hydrogen peroxide for 10 minutes to block the activity of endogenous tissue peroxidases. Subsequently, the tissue sections were incubated with an NF-κB p-p50 specific primary antibody at room temperature for 1 hour. The NF-κB p-p50 specific primary antibody used was NF-κB p-p50 (S337), sc-271908 (supplied by Santa Cruz Biotechnology).
[0195] Slides were stained using the standard EnVision+System-HRP kit (DAKO, Carpinteria, CA) according to the manufacturer's protocol. Immunohistochemical reactions were induced using diaminobenzidine as a chromogenic peroxidase substrate, and the slides were counterstained with hematoxylin. For negative control samples, non-immune IgG1 (Dako) was used instead of the primary antibody.
[0196] Target molecule-specific staining with suppressed background staining was observed in human tonsil and lymphoma samples using a 1:100 dilution of NF-κB p-p50 Ab (Figure 12C). Specifically, nuclear and / or cytoplasmic expression of NF-kappa B p-p50 was observed in all six SD cases treated with 50 mg QD (2 cases, tumor regression), 50 mg BID (1 case), 200 mg BID (1 case, tumor regression), and 400 BID (2 cases). NF-kappa B p-p50 expression was not detected in seven of the eight PD cases, including patients treated with 50 mg QD (1 case), 100 mg QD (1 case), 100 mg BID (3 cases), 200 mg BID (1 case), and 400 BID (1 case). A statistically significant correlation (p<0.05) was observed between NF-kappa B p-p50 expression and stable disease (SD) in tumor biopsy samples from NHL patients treated with compound 1. Analysis of NF-kappa B p-p50 expression in pairs of tumor biopsy samples (3 cases) collected before and after treatment with compound 1 revealed that NF-kappa B p-p50 expression in tumors from NHL patients treated with compound 1 was significantly downregulated. In in vitro experiments, NF-kappa B p-p50 expression was demonstrated in 3D lymphoma organoids treated with compound 1 at clinically appropriate concentrations. Our results support further exploration of NF-kappa B p-p50 as a promising predictive pharmacodynamic biomarker for IRAK4 inhibitors.
[0197] In summary, NF-kappa B p-p50 expression may serve as a useful biomarker to predict stable disease (SD) response to IRAK4-modified compound therapy in NHL patients. Using NF-kappa B p-p50 selection strategies in future clinical trials could identify NHL patients most likely to respond to IRAK4-modified compound therapy in combination with chemotherapy or targeted therapy.
[0198] Example 2: Performance of Compound 1 in WM The patient was a 49-year-old male who was otherwise healthy but complained of severe fatigue. Routine laboratory tests revealed a high erythrocyte sedimentation rate and marked anemia, and he was therefore referred to hematology / oncology. Further examination revealed IgM lambda m protein on serum protein electrophoresis, as well as multicellular bone marrow with three hematopoietic systems and atypical lymphoplasmacytic infiltration, consistent with WM. CT scan did not reveal lymphadenopathy or hepatosplenomegaly.
[0199] Treatment was recommended due to symptomatic cytopenia and severe fatigue. The patient was given rituximab-induced dose of 375 mg / m². 2The patient received IV once weekly for 8 weeks, followed by rituximab maintenance at 8 doses every 3 months from 2005 to 2007, achieving very good partial remission. The patient remained healthy for approximately 4 years, during which time the disease progressed, resulting in relapsing symptomatic anemia and new grade 1 peripheral sensory neuropathy, including in the hands and feet. The patient was retreated with rituximab from June to September 2011, during which time IgM levels increased from 1476 to 2042 mg / dL, and stable disease with no symptomatic improvement was achieved. A repeat bone marrow biopsy in November 2011 showed 90% cellular bone marrow, with WM accounting for 20% of cellularity, IgM lambda plasma cells accounting for 5-10% of cellularity, cytogenetics being normal, no increase in reticulin staining, and slight iron staining. CT scans at that time showed no lymphadenopathy or organ enlargement. By December 2012, the patient's serum IgM had increased to 3380 mg / dL and IgM-lambda m-protein was 2.37 g / dL. The patient was referred to a tertiary care center for further management, and autologous stem cell transplantation following induction chemotherapy was recommended. In early 2013, the patient received two cycles of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD), resulting in a decrease in IgM to 1285 mg / dL and m-protein to 0.88 g / dL, achieving partial remission (PR). Subsequently, in June 2013, the patient received rituximab, ifosfamide, etoposide chemical mobilization, and stem cell collection, after which IgM and m-protein levels remained unchanged. Further cytorelation using two cycles of bendamustine and rituximab (BR) before transplantation improved the partial response in patients (IgM 454 mg / dL, m protein 0.30 g / dL).Subsequently, in October 2013, the patient underwent autologous stem cell transplantation with BEAM conditioning (carmustine, etoposide, cytarabine, melphalan) without complications. The lowest post-transplant IgM level was 135 mg / dL, and m-protein became detectable by immunofixation only in January 2014, achieving a very good partial response (VGPR).
[0200] The patient remained asymptomatic for over four years, during which time m protein and IgM levels slowly increased. By mid-2017, the patient began experiencing increasing fatigue. A bone marrow evaluation in November 2017 revealed normal cell bone marrow and normal cytogenetics with 30% involvement by WM. Next-generation sequencing revealed RICTOR N1065S mutations, as well as MYD88 L265P and TET2 mutations in the subclonal population. There was no evidence of CXCR4 genomic alterations. By late 2018, fatigue began to interfere with the patient's ability to perform normal activities, and treatment was again recommended. Several options were discussed, including clinical trials and standard treatment of Bruton's tyrosine kinase inhibitor (BTKi) therapy. Considering the patient's medical history, current symptoms, known mutation landscape, and personal preferences, the patient was enrolled in a Phase 1 dose-escalation study of Compound 1, a novel oral IRAK4 inhibitor, in patients with relapsed or refractory B-cell malignancies (NCT03328078).
[0201] Baseline examinations in December 2018 included bone marrow biopsy showing 5–10% involvement by WM, m protein at 1.66 g / dL, IgM at 2,801 mg / dL, and computed tomography scans without pathological lymphadenopathy or hepatosplenomegaly. Quantitative immunoglobulin and serum protein electrophoresis were obtained in each cycle to determine the response to treatment (Figure 1).
[0202] The patient initiated treatment at an initial dose level of 50 mg. The patient was well-tolerated to treatment without adverse events. During the first six 21-day cycles, m protein tended to decrease slowly but steadily to 1.55 g / dL, and IgM initially increased from 2801 to 2866 mg / dL during the first two cycles, then decreased to 2639 by day 1 of cycle 6 (Figure 1). Using a standard 3+3 design, the subsequent dose level of 100 mg po BID was cleared protocol by protocol. Given the evidence of a response without notable toxicity, the patient was candidate for escalation to 100 mg po BID in April 2019, starting on day 1 of cycle 7. The patient maintained stable disease (SD) with a decreasing trend in IgM and m-protein levels during cycles 7 and 8, without evidence of toxicity, and was therefore a candidate for escalation to the next clear dose level of 200 mg po BID, starting on day 1 of cycle 9 in May 2019. Prior to the 200 mg BID dose escalation, baseline IgM was 2245 mg / dL and m-protein was 1.37 g / dL. Baseline symptoms of fatigue showed slight improvement but persisted. The patient continued to enjoy a seemingly dose-dependent decrease in tumor markers at the 200 mg po BID dose level, and fatigue was completely resolved by the summer of 2019. The patient reported a significant improvement in quality of life with the resolution of fatigue and returned to a rigorous daily exercise program that had been impossible for the previous two years due to WM-related symptoms. In August 2019, the patient was found to have asymptomatic grade 2 creatine phosphokinase (CPK) elevation that was not apparent on extensive and physical examinations. The patient reduced the intensity of their exercise program, and the asymptomatic CPK elevation resolved completely without requiring delay or reduction of the compound 1 dose. During cycles 15–20, at a 200 mg po BID dose, the patient's IgM plateaued at approximately 1500 mg / dL and m-protein plateaued at approximately 0.9 g / dL. Based on the development of safety data at higher dose levels, the patient was escalated to a 300 g po BID starting in cycle 20 in January 2020.The patient again experienced a seemingly dose-dependent response without significant toxicity and achieved a partial response (PR) on day 1 of C22 (m protein 0.68 g / dL, IgM 1241 mg / dL). The patient is maintaining compound 1 300 mg po BID.
[0203] Treatment in WM involves targeting pathways associated with known mutations in MYD88 and CXCR-4. Previous studies have shown the role of IRAK4 in the signaling cascade, which is involved in the stimulating effect of inflammatory cytokines by forming a complex with MYD88. Therefore, IRAK4 is an essential component in modulating the immune response, and dysfunction in any part of the complex can lead to immunodeficiency or immunodysregulation. Addition of IRAK4 inhibitors leads to a strong association between IRAK4 and MYD88 and a weak association with IRAK-1, and thus, the reduction in IRAK1 ubiquitination ultimately results in a decrease in IL-1-induced signaling and cytokine production.
[0204] By inhibiting IRAK4, compound 1 prevents NF-κB activation, resulting in reduced inflammatory cytokine production and potential antitumor, immunomodulatory, and anti-inflammatory effects. Preclinical studies also suggest that compound 1 affects TLR / IL1R signaling, which may interfere with inflammatory processes in autoimmune states.
[0205] This patient received well-tolerated continuous oral treatment with compound 1 for nearly 18 months. The patient's tumor burden decreased in a dose-dependent manner, and a partial response (PR) was achieved according to the 6th International Workshop on WM Response Criteria (Figure 1). The patient's quality of life improved from baseline, with reduced fatigue, and even allowed for the vigorous physical exercise enjoyed before the onset of the disease. However, this resulted in intermittent asymptomatic grade 2 CK elevations, which were resolved by reducing exercise without the need to maintain or reduce exposure to compound 1.
[0206] Example 3: Performance of Compound 1 in DLBCL, FL, HGBL, WM, LPL, MZL, and MCL Test design and method The Phase I study compound 1 was a dose-escalation study using a 3+3 design. Seven dosing cohorts included daily continuous oral monotherapy of 50 and 100 mg QDs, and 50, 100, 200, 300, or 400 mg BIDs in 21-day cycles. Objectives included safety and tolerability (primary), pk / pd and early efficacy (secondary), and biomarker correlation (exploratory). Thirty-one patients with resistant or refractory progressive NHL were enrolled. Details of the patient population are shown in Table 1 below.
[0207] [Table 1]
[0208] result Compound 1 was well-tolerated. Eight patients were exposed to the highest dose level of 400 mg BID: Two of the five DLT-evaluable patients experienced grade 3 rhabdomyolysis (DLT) without complications or reversibility after treatment interruption and hydration / analgesia (both subsequently continued treatment with lower doses of 200 or 300 mg BID, respectively). Six patients were well-tolerated to 300 mg BID without DLT. Most non-hematological TEAEs were grade 1 or 2 and were manageable, including diarrhea, vomiting, fatigue, dyspnea, and myalgia. Mild / moderate, neutropenia, anemia, thrombocytopenia; at dose levels ranging from 200 to 400 mg BID, there were only four combinations of grade 3 episodes in 18 patients without complications (Table 2). No toxic deaths. Pharmacokinetics showed favorable characteristics with increasing exposure proportional to the dose. Similar pharmacodynamic changes were observed in cytokine reduction. Treatment duration ranged from less than 1 month to over 18 months, and disease control was sustained. Eight of 28 evaluable patients experienced a reduction of ≥20% in total tumor volume from baseline (more significant at higher doses) (Table 4). WM patients with persistent partial response underwent intra-patient dose escalation and demonstrated a well-defined dose / response relationship and very good treatment tolerability (Figure 3). Molecular properties, including downstream pharmacodynamic markers and origin cells of IRAK4, are shown.
[0209] [Table 2]
[0210] [Table 3]
[0211] [Table 4]
[0212] In summary, compound 1 demonstrated good safety and tolerability, desirable pharmacokinetic properties, and preliminary clinical activity.
[0213] Example 4: Performance of Compound 1 in AML and MDS Test design and method This is a single-arm, dose-escalation phase 1 trial of orally administered compound monotherapy in adult patients with AML or high-risk MDS (NCT04278768). The trial will be conducted in two parts: an initial dose escalation phase and a dose expansion phase. The starting dose level is 200 mg BID, which has been determined to be safe and can not only achieve the relevant level of drug exposure but also demonstrate signs of biological activity and clinical efficacy in the NHL trial. Three patients with AML or MDS will be enrolled at the specified dose. If none of the first three patients experience a dose-limiting trial (DLT) during the first cycle, the patient may be enrolled at the next higher dose level, 300 mg BID, until a safe and effective RP2D is established.
[0214] This trial is expected to enroll approximately 18 patients to establish an initial RP2D. The safety population will include all patients in the trial who received any dose of compound 1, and the efficacy population will include patients who have a valid baseline and post-baseline disease assessment and who have received at least one dose of the study drug. Each treatment cycle of compound 1 will be 28 days long and repeated in the absence of toxicity or disease progression.
[0215] The main inclusion and exclusion criteria for the study are as follows: Relapsed or refractory AML (including primary or secondary, treatment-related) following at least one standard treatment (including chemotherapy, reinduction therapy, or stem cell transplantation) based on the investigator's assessment after at least six cycles of hypomethylating agent [HMA] or evidence of early progression, or assessment of high-risk / very high-risk relapsed / refractory MDS (IPSS-R criteria). Patients diagnosed with acute promyelocytic leukemia (APL, M3), acute transformation phase of CML, allogeneic hematopoietic stem cell transplant (Allo-HSCT) within 60 days of the first dose of compound 1, or clinically significant graft-versus-host disease (GVHD) requiring continuous escalation of immunosuppressants prior to initiation of compound 1 are excluded.
[0216] The primary objective is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of compound 1 in patients with AML and high-risk MDS, based on safety and tolerability, DLT, and PK / PD findings.
[0217] result All initial patients completed Cycle 1 with myeloblastopenia, including some complete myelo-responses. Cohort 1 (200 mg BID, cycle duration 4 weeks) All three patients with hr-MDS are continuing treatment (currently on cycles 2-4). This is their first cycle without DLT. For Grade 3 dizziness, a 1-dose reduction was C2. Cohort 2 (300mg BID) Four patients (three with AML, one with hr-MDS), all continuing treatment (currently 1-2 cycles). The first three patients did not undergo DLT. Cohort 3 Open (400mg BID) Registration is open.
[0218] Example 5: Performance of Compound 1 in recurrent or refractory hematological malignancies Test design and method This is a study of Compound 1 administered orally in combination with ibrutinib in adult patients with relapsed or refractory hematological malignancies (NCT03328078). It has two parts: an initial dose escalation phase (Part A2) and an expansion phase involving four cohorts. In a 3x3 dose escalation design, the starting oral dose of Compound 1 is 200 mg BID, administered daily. Simultaneously, patients receive ibrutinib daily at a labeled dose (560 mg or 420 mg) for their respective NHL subtype. If well tolerated, the dose of Compound 1 is escalated to 300 mg BID. Objectives include safety / tolerance, pharmacokinetics, preliminary efficacy evaluation, and exploratory biomarker correlations. Once a recommended Phase 2 dose (RP2D) for the combination dose is determined, the expansion phase (Part B) will evaluate the efficacy (CR / ORR rate / duration), safety / tolerability, population PK, and biomarker correlations of the combination of Compound 1 and ibrutinib. Part B includes four cohorts, including 1-MZL, 2-DLBCL, 3-CNSL, and 4-NHL, which exhibit ibrutinib-resistant characteristics (basket design).
[0219] Cohorts 1-3 must be BTK inhibitor naive. The latter group received ibrutinib monotherapy and responded (no primary resistance). When patients develop adaptive secondary resistance and show tumor progression, they should be administered in combination with compound 1. (Ibrutinib treatments at short intervals of less than 3 weeks are acceptable.) This cohort includes patients with ibrutinib approval or NCCN recommended indications: MCL, MZL, CLL / SLL, WM / LPL, PCNSL (listed in NCCN).
[0220] Primary objective: To identify preliminary efficacy signals of improved objective responses in cohorts 1-3 compared to past data, and to demonstrate reversal of resistance in cohort 4 by showing objective responses after preceding progression.
[0221] The estimated sample size of approximately 18 patients in Part A2 is based on a standard 3+3 study design for dose escalation. The exact number of patients will be determined by the number of cohorts required to establish the maximum tolerable dose (MTD) and recommended phase 2 dose (RP2D) for compound 1 when administered in combination with ibrutinib. For dose expansion in Part B, up to 46 patients will be enrolled in each of the four NHL cohorts. The safety population will include all patients in studies who received any dose of compound 1 in combination with ibrutinib, and the efficacy population will include patients who have valid baseline and post-baseline disease assessments and who received at least one dose of the combination study drug. Safety observations and measurements will include drug exposure, AEs, safety clinical laboratory tests, vital signs, physical examination, ECG, and ECOG performance status. Each treatment cycle of compound 1 will be 21 days long and repeated in the absence of toxicity or tumor progression, with ibrutinib administered as labeled.
[0222] The primary inclusion and exclusion criteria for Part A2 of the combination therapy dose escalation study are as follows: a histopathologically confirmed diagnosis of B-cell NHL according to the WHO 2016 classification. Eligible NHL subtypes include follicular lymphoma, MZL, mantle cell lymphoma, DLBCL (including leg, testicular, or unspecified extranodal lymphoma), CLL / SLL, primary or secondary CNS lymphoma, and Waldenström macroglobulinemia / LPL. Patients with mantle cell lymphoma, MZL, WM / LPL, or CLL / SLL must meet the clinical criteria for the necessary treatment of their disease. Patients with acute or chronic toxicity resulting from previous anticancer therapy, excluding alopecia, that has not been resolved to grade 1 or lower as determined by NCI CTCAE v4.03 within 7 days prior to the start of the study will be excluded.
[0223] The study treatment endpoint is to determine the safety and tolerability, DLT, MTD, and RP2D of oral compound 1 in combination with ibrutinib, while the secondary endpoint is to evaluate the objective response rate (ORR), duration response rate (DOR), DCR, PFS, and OS after treatment with compound 1 in combination with ibrutinib.
[0224] Example 6: Performance of Compound 1 in Autoimmune Diseases Compound 1 is administered to subjects suffering from an autoimmune condition (e.g., graft-versus-host disease) in a dose-escalation study starting at 50 mg. The efficacy of Compound 1 is determined by methods known to those skilled in the art.
[0225] Example 7: Treatment of OCL-LY10 cells and TF-1 cells with compound 1 OCL-LY10 and TF-1 cells were treated with compound 1 at different concentrations of 3 μM and 10 μM. Cell solubilates were obtained 48 hours after treatment. Protein sample concentrations were quantified, and total protein extracts, each adjusted to 20 μg, were loaded into each well of an SDS-polyacrylamide gel. Cell extracts were separated by 10% SDS-PAGE, transferred to a nitrocellulose membrane, and explored as shown. The following antibodies were used for immunoblot analysis: NF-κB p-p50 S337 (Santa Cruz Biotechnology) and β-actin (Cell Signaling Technology). Expression of NF-κB p-p50 S337 was downregulated in OCL-Ly10 and TF-1 cell lines treated with compound 1.
[0226] Built-in by reference All publications and patents referenced herein are incorporated herein by reference in whole, as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. In case of any conflict, including the definitions herein, this application shall prevail.
[0227] Equal portions While specific embodiments of the subject matter disclosure have been discussed, the above specification is illustrative and not limiting. Many variations of this disclosure will become apparent to those skilled in the art upon consideration of this specification and the following claims. The full scope of this disclosure should be determined by referring to the claims, together with the full scope of equivalents, and the specification, together with such variations.
Claims
1. A pharmaceutical composition comprising an IRAK4 inhibitor or an IRAK4 degrader for use in treating a disease or disorder in a subject identified as having elevated phosphorylated NF-κB expression compared to a reference level of expression of phosphorylated NF-κB.
2. 2. The pharmaceutical composition for use according to claim 1, wherein the reference level is a value obtained from one or more subjects not affected by the disease or disorder.
3. The pharmaceutical composition for use according to claim 2 , wherein the value is obtained from the same biological source (e.g. tissue, blood, or other bodily fluid) as the biological sample.
4. 4. The pharmaceutical composition for use according to claim 2 or 3, wherein the value is obtained from tissue or blood.
5. The pharmaceutical composition for use according to any one of claims 1 to 4, wherein the phosphorylated NF-κB is NF-κB pp50.
6. The pharmaceutical composition for use according to claim 5, administered only if the expression level of NF-κB p-p50 in the sample is elevated compared to the reference level.
7. The pharmaceutical composition for use according to any one of claims 1 to 6, wherein the expression of NF-κB p-p50 is nuclear expression.
8. The pharmaceutical composition for use according to any one of claims 1 to 6, wherein the expression of NF-κB p-p50 is a cytoplasmic expression.
9. The pharmaceutical composition for use according to any one of claims 1 to 6, wherein the expression of NF-κB p-p50 is a combined nuclear and cytoplasmic expression.
10. The pharmaceutical composition for use according to any one of claims 1 to 4, wherein the phosphorylated NF-κB is NF-κB p-p65.
11. The pharmaceutical composition for use according to claim 10, which is administered only if the expression level of NF-κB p-p65 in the sample is elevated compared to the reference level.
12. The pharmaceutical composition for use according to claim 10 or 11, wherein the expression of NF-κB p-p65 is nuclear expression.
13. The pharmaceutical composition for use according to claim 10 or 11, wherein the expression of NF-κB p-p65 is cytoplasmic expression.
14. The pharmaceutical composition for use according to any one of claims 10 to 13, wherein the expression of NF-κB p-p65 is a combined nuclear and cytoplasmic expression.
15. A pharmaceutical composition for use according to any one of claims 1 to 14, comprising an IRAK4 inhibitor.
16. The IRAK4 inhibitor has formula I: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof is represented by During the ceremony, X 1 and X 3 is independently CH or N; X 2 But, CR 2 or N, with the proviso that X 1 , X 2 , or X 3 is N, A is O or S; Y is -CH 2 - or O, Z is aryl or heterocyclyl; R 1 is, independently at each occurrence, halo or optionally substituted heterocyclyl, said substituents being alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl, or -NR a R b and R 2 is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or -NR a R b wherein the substituents are alkyl, amino, halo, or hydroxyl; R 3 is, for each occurrence, alkyl or hydroxyl; R a and R b is independently hydrogen, alkyl, acyl, or heterocyclyl; "m" and "n" are independently 0, 1, or 2; The pharmaceutical composition for use according to any one of claims 1 to 14, wherein "p" is 0 or 1.
17. A is O or S; Y is -CH 2 - or O, Z is aryl or heterocyclyl; R 1 is, independently at each occurrence, halo or optionally substituted heterocyclyl, said substituents being alkyl, aminoalkyl, halo, or -NR a R b and R a and R b is independently hydrogen, alkyl, or heterocyclyl; R 2 is hydrogen, cycloalkyl, heterocyclyl, or -NR a R b and "m" is 0, 17. The pharmaceutical composition for use according to claim 16, wherein "n" is 1.
18. A is O or S; Y is -CH 2 - or O, Z is aryl or heterocyclyl; R 1 is, independently at each occurrence, halo or optionally substituted heterocyclyl, said substituents being alkyl, alkoxy, aminoalkyl, halo, hydroxyl, or -NR a R b and R a and R b is independently hydrogen, alkyl, or heterocyclyl; R 2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl, or -NR a R b wherein the substituents are selected from amino, halo, or hydroxyl; "m" and "n" are independently 0, 1, or 2; 17. The pharmaceutical composition for use according to claim 16, wherein "p" is 0 or 1.
19. 【Fig. 2】 but, 【Chemistry 3】 The pharmaceutical composition for use according to any one of claims 16 to 18,
20. The pharmaceutical composition for use according to any one of claims 16 to 19, wherein Z is aryl or 5- or 6-membered heterocyclyl.
21. Z is phenyl, or furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1H-tetrazolyl, oxadiazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, azetidinyl, oxetanyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazin ... and optionally substituted heterocyclyl selected from phenyl, morpholinyl, thiomorpholinyl, 1,4-dioxanyl, dioxidethiomorpholinyl, oxapiperazinyl, oxapiperidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiophenyl, dihydropyranyl, and azabicyclo[3.2.1]octanyl, each of which is selected from alkyl, alkoxy, halo, hydroxyl, hydroxyalkyl, or -NR a R b Optionally replaced by R a and R b The pharmaceutical composition for use according to any one of claims 16 to 20, wherein is independently hydrogen, alkyl, or acyl.
22. The IRAK4 inhibitor has formula (IA): 【Chemistry 4】 17. The pharmaceutical composition for use according to claim 16, represented by: or a pharma- ceutically acceptable salt thereof.
23. A is O or S; Y is -CH 2 - or O, R 1 is, independently at each occurrence, halo or optionally substituted heterocyclyl, said substituents being alkyl, aminoalkyl, halo, or -NR a R b and R a and R b is independently hydrogen, alkyl, or heterocyclyl; R 2 is hydrogen, cycloalkyl, heterocyclyl, or -NR a R b and "m" is 0, 23. The pharmaceutical composition for use according to claim 22, wherein "n" is 1.
24. A is O or S; Y is -CH 2 - or O, R 1 is, independently at each occurrence, halo or optionally substituted heterocyclyl, said substituents being alkyl, alkoxy, aminoalkyl, halo, hydroxyl, or -NR a R b and R a and R b is independently hydrogen, alkyl, or heterocyclyl; R 2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl, or -NR a R b wherein the substituents are selected from amino, halo, or hydroxyl; 23. The pharmaceutical composition for use according to claim 22, wherein "m" and "n" are independently 0, 1, or 2.
25. The IRAK4 inhibitor has formula (IB): 【Chemistry 5】 17. The pharmaceutical composition for use according to claim 16, represented by: or a pharma- ceutically acceptable salt thereof.
26. A is O or S; Y is -CH 2 - or O, R 1 is, independently at each occurrence, halo or optionally substituted heterocyclyl, said substituents being alkyl, aminoalkyl, halo, or -NR a R b and R a and R b is independently hydrogen, alkyl, or heterocyclyl; R 2 is hydrogen, cycloalkyl, heterocyclyl, or -NR a R b and 26. The pharmaceutical composition for use according to claim 25, wherein "n" is 1.
27. A is O or S; Y is -CH 2 - or O, R 1 is, independently at each occurrence, halo or optionally substituted heterocyclyl, said substituents being alkyl, alkoxy, aminoalkyl, halo, hydroxyl, or -NR a R b and R a and R b is independently hydrogen, alkyl, or heterocyclyl; R 2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl, or -NR a R b wherein the substituents are selected from amino, halo, or hydroxyl; 26. The pharmaceutical composition for use according to claim 25, wherein "m" and "n" are independently 0, 1, or 2.
28. The compound of formula (I) is represented by formula (IC) 【Chemistry 6】 17. The pharmaceutical composition for use according to claim 16, which is a compound of the formula:
29. R 1 is an optionally substituted heterocyclyl, said substituents being alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl, or -NR a R b and R a and R b The pharmaceutical composition for use according to any one of claims 16 to 28, wherein is independently hydrogen or acyl.
30. R 1 is an optionally substituted heterocyclyl, said substituents being alkyl, aminoalkyl, halo, or -NR a R b and R a and R b The pharmaceutical composition for use according to any one of claims 16 to 28, wherein is independently hydrogen or acyl.
31. R 1 is an optionally substituted heterocyclyl, said substituents being alkyl, aminoalkyl, halo, or -NR a R b and R a and R b The pharmaceutical composition for use according to any one of claims 16 to 28, wherein is independently hydrogen, alkyl, or heterocyclyl.
32. R 1 is an optionally substituted heterocyclyl, said substituents being alkyl, alkoxy, aminoalkyl, halo, hydroxyl, or -NR a R b and R a and R b The pharmaceutical composition for use according to any one of claims 16 to 28, wherein is independently hydrogen, alkyl, or heterocyclyl.
33. R 1 The pharmaceutical composition for use according to any one of claims 16 to 32, wherein is pyridyl, pyrazolyl, pyrrolidinyl, or piperidinyl.
34. R 1 is an optionally substituted pyrazolyl, said substituents being alkyl, hydroxyl, or -NR a R b The pharmaceutical composition for use according to any one of claims 16 to 28,
35. R 1 The pharmaceutical composition for use according to any one of claims 16 to 28, wherein is halo.
36. R 2 is hydrogen, cycloalkyl, heterocyclyl, or -NR a R b The pharmaceutical composition for use according to any one of claims 16 to 35,
37. R 2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl, or -NR a R b 36. The pharmaceutical composition for use according to any one of claims 16 to 35, wherein said substituents are selected from amino, halo, or hydroxyl.
38. R 2 36. The pharmaceutical composition for use according to any one of claims 16 to 35, wherein is an optionally substituted heterocyclyl selected from piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, azetidinyl, pyrazolyl, furanyl, or azabicyclo[3.2.1]octanyl, said substituents being hydroxyl, halo, alkyl, or amino.
39. R 2 The pharmaceutical composition for use according to any one of claims 16 to 35, wherein is piperidinyl, pyrrolidinyl, morpholinyl, or piperazinyl.
40. R 2 The pharmaceutical composition for use according to any one of claims 16 to 35, wherein is hydrogen.
41. R 2 The pharmaceutical composition for use according to any one of claims 16 to 35, wherein is cycloalkyl.
42. R 2 42. The pharmaceutical composition for use according to claim 41 , wherein is cyclopropyl.
43. R 3 The pharmaceutical composition for use according to any one of claims 16 to 42, wherein is alkyl.
44. The pharmaceutical composition for use according to any one of claims 16 to 43, wherein m is 0 and p is 1.
45. 44. The pharmaceutical composition for use according to any one of claims 16 to 43, wherein m is 0 or 2 and p is 0 or 1.
46. The IRAK4 inhibitor is 6'-amino-N-(2-morpholinoxazolo[4,5-b]pyridin-6-yl)-[2,3'-bipyridine]-6-carboxamide, 6'-amino-N-(5-cyclopropyl-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-[2,3'-bipyridine]-6-carboxamide hydrochloride, N-(5-cyclopropyl-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride, N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-yl)picolinamide hydrochloride, N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-yl)picolinamide, 2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 6-chloro-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)picolinamide, N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-6-(1-methyl-1H-pyrazol-4-yl)picolinamide, 2-(2-chloropyridin-4-yl)-N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, (S)-2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(pyrrolidin-3-ylamino)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 6'-amino-N-(2-morpholinoxazolo[5,4-b]pyridin-5-yl)-[2,3'-bipyridine]-6-carboxamide, 6'-amino-N-(2-morpholinothiazolo[4,5-c]pyridin-6-yl)-[2,3'-bipyridine]-6-carboxamide, 6'-amino-N-(2-morpholinothiazolo[5,4-b]pyridin-5-yl)-[2,3'-bipyridine]-6-carboxamide, 2-(2-methylpyridin-4-yl)-N-(2-morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 6'-amino-N-(2-morpholinothiazolo[4,5-b]pyridin-6-yl)-[2,3'-bipyridine]-6-carboxamide, N-(2-morpholinothiazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-yl)picolinamide, 3-(4-(aminomethyl)piperidin-1-yl)-5-fluoro-N-(2-morpholinothiazolo[4,5-b]pyridin-6-yl)benzamide, 2-(4-(aminomethyl)piperidin-1-yl)-5-fluoro-N-(2-morpholinothiazolo[4,5-b]pyridin-6-yl)benzamide, 2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-yl)picolinamide, N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-6-(1H-pyrazol-4-yl)picolinamide, N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(2,5-dimorpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(4-methylpiperazin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide, N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-3-yl)oxazole-4-carboxamide, N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-hydroxypyridin-3-yl)oxazole-4-carboxamide, 2-(2-hydroxypyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(6-hydroxypyridin-3-yl)oxazole-4-carboxamide, 2-(2-methoxypyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 2-(2-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 2-(3-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(3-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(6-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 6-(1-methyl-1H-pyrazol-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)picolinamide, N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(6-methylpyridin-3-yl)oxazole-4-carboxamide, (S)—N-(5-(3-aminopyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (S)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (R)—N-(5-(3-aminopyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (R)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (S)-2-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, (S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)picolinamide, (S)-6-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)picolinamide, (S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, (S)—N-(5-cyclopropyl-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(3-hydroxypyrrolidin-1-yl)oxazole-4-carboxamide, (S)-2-(3-aminopyrrolidin-1-yl)-N-(5-cyclopropyl-2-morpholinoxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 2-(2-methylpyridin-4-yl)-N-(5-(piperidin-1-yl)-2-(pyrrolidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide hydrochloride, N-(2-(2,6-dimethylmorpholino)-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride, N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-6-(1-methyl-1H-pyrazol-4-yl)picolinamide hydrochloride, 6-(1-methyl-1H-pyrazol-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)picolinamide, N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-3-yl)oxazole-4-carboxamide hydrochloride, N-(2-((2S,6R)-2,6-dimethylmorpholino)-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 2-(2-hydroxypyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methoxypyridin-4-yl)oxazole-4-carboxamide, 2-(6-methoxypyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 2-(2-methoxypyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, (S)—N-(5-(3-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(6-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 2-(3-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, (S)-6-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)picolinamide, (S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)picolinamide, (S)-6-(3-aminopyrrolidin-1-yl)-N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)picolinamide, (S)—N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide, (S)-2-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, (S)—N-(5-(3-aminopyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (S)-2-(3-aminopyrrolidin-1-yl)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, (S)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (S)—N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide, (S)—N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(3-hydroxypyrrolidin-1-yl)oxazole-4-carboxamide, (S)—N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)picolinamide, (S)—N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)oxazole-4-carboxamide, N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide, (S)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide, (R)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide, (S)—N-(5-(azetidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide, N-(5-(3-hydroxyazetidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (S)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)thiophene-2-carboxamide, (S)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide, (S)—N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide (R)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide, N-(5-(azetidin-1-yl)-2-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridin-4-yl)-N-(2-(piperidin-1-yl)-5-(pyrrolidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(pyrrolidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 5-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)furan-2-carboxamide, N-(5-(azepan-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(2-aminopyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide hydrochloride, N-(5-(azetidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (R)—N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (R)—N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide, (S)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)picolinamide N-(5-(4-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide N-(5-(4-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride N-(5-(1-methyl-1H-pyrazol-4-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(3-fluorophenyl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide, N-(5-(3-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide, (S)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide, N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (R)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide, N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide, (S)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide, (S)—N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)thiophene-2-carboxamide, N-(5-(azetidin-1-yl)-2-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridin-4-yl)-N-(2-(piperidin-1-yl)-5-(pyrrolidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 5-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)furan-2-carboxamide, N-(5-(azetidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(pyrrolidin-1-yl)oxazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide, (R)—N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide, N-(5-(furan-3-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(3-fluoropiperidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(4-fluoropiperidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, (S)—N-(5-(3-aminopiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(1H-pyrazol-4-yl)thiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, N-(5-(6-fluoropyridin-3-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(2-(3-hydroxypiperidin-1-yl)-5-(piperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(2-acetamidopyridin-4-yl)-N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, N-(2-(3-hydroxypiperidin-1-yl)-5-(4-hydroxypiperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, 2-(2-acetamidopyridin-4-yl)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide, 2-(2-aminopyridin-4-yl)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide hydrochloride, 5-(2-aminopyridin-4-yl)-N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)furan-3-carboxamide hydrochloride, 2-(2-aminopyridin-4-yl)-N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide hydrochloride, 2-(2-aminopyridin-4-yl)-N-(5-(4-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)oxazole-4-carboxamide hydrochloride, N-(5-(2-fluoropyridin-4-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(4-fluoropiperidin-1-yl)-2-(3-hydroxypiperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, N-(5-(4-aminopiperidin-1-yl)-2-(3-hydroxypiperidin-1-yl)thiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride, and N-(5-(2-hydroxypyridin-4-yl)-2-morpholinothiazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride, or a pharma- ceutically acceptable salt or stereoisomer thereof.
47. The IRAK4 inhibitor is 【Chemistry 7】 The pharmaceutical composition for use according to any one of claims 1 to 15,
48. The IRAK4 inhibitor is 【Chemistry 8】 The pharmaceutical composition for use according to any one of claims 1 to 15, which is a pharma- ceutically acceptable salt of:
49. The IRAK4 inhibitor, 【Chemistry 9】 or a pharma- ceutically acceptable salt thereof.
50. The IRAK4 inhibitor, 【Chemistry 10】 or a pharma- ceutically acceptable salt thereof.
51. The IRAK4 inhibitor, 【Chemistry 11】 or a pharma- ceutically acceptable salt thereof.
52. The IRAK4 inhibitor, 【Chemistry 12】 or a pharma- ceutically acceptable salt thereof.
53. The IRAK4 inhibitor, 【Chemistry 13】 or a pharma- ceutically acceptable salt thereof.
54. 49. A pharmaceutical composition for use according to claim 47 or 48, comprising 100-400 mg of said IRAK4 inhibitor and adapted for administration twice daily.
55. 49. The pharmaceutical composition for use according to claim 47 or 48, comprising about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg of said IRAK4 inhibitor and adapted for administration twice daily.
56. 49. The pharmaceutical composition for use according to claim 47 or 48, comprising about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg of said IRAK4 inhibitor and adapted for once-daily administration.
57. The pharmaceutical composition for use according to any one of claims 1 to 14, wherein said IRAK4 inhibitor is PF-06650833 or BAY1830839.
58. A pharmaceutical composition for use according to any one of claims 1 to 14, comprising an IRAK4 degrading agent.
59. The pharmaceutical composition for use according to claim 58, wherein said IRAK4 degrading agent is KT-474.
60. A pharmaceutical composition for use according to any one of claims 1 to 59, co-administered with a BCL-2 inhibitor.
61. The pharmaceutical composition for use according to claim 60, wherein the BCL-2 inhibitor is venetoclax.
62. A pharmaceutical composition for use according to any one of claims 1 to 61, co-administered with a BTK inhibitor.
63. 63. The pharmaceutical composition for use according to any one of claims 1 to 62, wherein the disease or disorder is cancer.
64. 64. The pharmaceutical composition for use according to any one of claims 1 to 63, wherein the disease or disorder is a hematological malignancy.
65. 65. The pharmaceutical composition for use according to claim 64, wherein the hematological malignancy is non-Hodgkin's lymphoma.
66. 65. The pharmaceutical composition for use according to claim 64, wherein the hematological malignancy is leukemia or lymphoma.
67. The hematological malignancies include myelogenous leukemia, myeloid leukemia (e.g., acute myeloid leukemia), myelodysplastic syndrome, lymphoblastic leukemia (e.g., acute lymphoblastic leukemia), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high-risk CLL, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL) (e.g., DLBCL or ABC-DLBLC), mantle cell lymphoma (MCL), Waldenström-Stokes lymphoma (WSL), or leukemia (LE).
67. The pharmaceutical composition for use according to any one of claims 64 to 66, wherein the cancer is mucoglobulinemia (WM), multiple myeloma, marginal zone lymphoma (MZL), Burkitt's lymphoma, non-Burkitt's high-grade B-cell lymphoma, extranodal marginal zone B-cell lymphoma, transformed high-grade B-cell lymphoma (HGBL), lymphoplasmacytic lymphoma (LPL), central nervous system lymphoma (CNSL), or MALT lymphoma.
68. 68. The pharmaceutical composition for use according to any one of claims 64 to 67, wherein the hematological malignancy is recurrent.
69. 69. The pharmaceutical composition for use according to any one of claims 64 to 68, wherein the hematological malignancy is refractory.
70. 70. The pharmaceutical composition for use according to any one of claims 1 to 69, wherein the disease or disorder is resistant to treatment with a BTK inhibitor.
71. 71. The pharmaceutical composition for use according to claim 70, wherein the disease or disorder is resistant to treatment with ibrutinib, acalabrutinib, zanubrutinib, evobrutinib, ONO-4059, spebrutinib, or HM7 1224.
72. 71. The pharmaceutical composition for use according to claim 70, wherein the disease or disorder is resistant to treatment with ibrutinib.
73. 63. The pharmaceutical composition for use according to any one of claims 1 to 62, wherein the disease or disorder is an inflammatory disease or disorder.
74. 74. The pharmaceutical composition for use according to claim 73, wherein the inflammatory disease or disorder is an autoimmune disease or disorder.
75. 74. The pharmaceutical composition for use according to claim 73, wherein the inflammatory disease or disorder is graft-versus-host disease (GVHD).
76. A pharmaceutical composition for use according to any one of claims 1 to 72, administered to a subject who has previously received at least one anti-cancer therapy (e.g., an anti-cancer therapy or an anti-inflammatory therapy).
77. A pharmaceutical composition for use according to any one of claims 1 to 76, administered to a subject having a mutation in RICTOR.
78. A pharmaceutical composition for use according to any one of claims 1 to 76, administered to a subject having an N1065S mutation in RICTOR.
79. A pharmaceutical composition for use according to any one of claims 1 to 78, administered to a subject having a mutation in MYD88.
80. A pharmaceutical composition for use according to any one of claims 1 to 78, administered to a subject having an L265P mutation in MYD88.
